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  Tumors of neuroectodermal origin are among the most aggressive and treatment-
refractory forms of human cancer. While such tumors arise from a variety of defects, two key 
targets are the transcription factors p53 and OLIG2. We have developed stabilized peptides to 
study and target deregulated p53 and OLIG2 pathways in neuroectodermal cancers. 
PUMA (p53-upregulated modulator of apoptosis) is a BH3-only member of the BCL-2 
protein family that regulates apoptosis in response to p53-dependent and p53-independent 
stress signals. The specific interactions that mediate the pro-apoptotic activity of PUMA remain 
controversial. We generated stabilized alpha-helices of BCL-2 domains (SAHB) peptides 
modeled after the BH3 effector domain of PUMA. Structural analyses determined that PUMA 
SAHB contacts BAX at both the N-terminal α1/α6 trigger site and the canonical BH3 binding 
pocket, binding events that functionally activate BAX. Notably, both PUMA SAHB and PUMA 
protein pull-downs identified anti- and pro-apoptotic binding partners in a cellular context. As 
PUMA has been implicated in driving apoptosis in multiple neural cell types, we further 
demonstrated that treatment of neuroblastoma cell lines with a cell-permeable PUMA SAHB 
analog triggered dose-dependent apoptosis. Together, we find that the PUMA BH3 domain 
activates apoptosis through multimodal interactions with BCL-2 family proteins, and its mimetics 
may serve as prototype therapeutics in tumors of neural origin. 
Whereas suppression of p53 signaling and apoptosis are features of diverse tumor 
types, the basic helix-loop-helix (bHLH) transcription factor OLIG2 is selectively overexpressed 
in gliomas. Early in development, OLIG2 is responsible for maintaining progenitor cells in a 	 ﾠ iv	 ﾠ
replication-competent state. Tumor stem cells are believed to co-opt this OLIG2 functionality to 
continually repopulate glial tumors. To achieve its transcriptional function, OLIG2 must dimerize 
via its bHLH domain. Stabilized alpha-helices of OLIG2 (SAH-OLIG2) peptides of the OLIG2 
bHLH domain were generated in an effort to disrupt this pathologic dimerization. While helical 
stabilization of several SAH-OLIG2 peptides was achieved, specific engagement and disruption 
of the native bHLH dimer did not occur, informing alternative design strategies for future 
targeting efforts. These studies underscored the importance of interrogating the OLIG2 dimeric 
structure and catalyzed the discovery of candidate OLIG2 interaction partners for therapeutic 
targeting. 
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Chapter 1 
 
Introduction   2 
I. Protein-protein interactions 
Since their discovery in the mid-19
th century
1, proteins have long proven critical to the 
inner workings of cells. The vast majority of cellular functions are carried out by proteins, leading 
one early scientist to ask “[w]ould it be far from the truth, therefore, to look upon the enzyme as 
the chemical basis of life?”
2 A proteinʼs regulatory function is carried out by its physical 
interactions with cellular metabolites, lipids, nucleic acids, and other proteins. The nature of 
these protein-protein interactions (PPIs) and the ability to selectively activate or disrupt them 
continues to be the subject of intense exploration and is the basis for this thesis. 
 
Protein structure and function 
Protein structure and function are intimately intertwined, and thus in order to understand 
how proteins work, one must delve into their structure. Protein structure can be organized into 
four tiers: primary, secondary, tertiary, and quaternary structure. A proteinʼs primary structure 
consists of its amino acid sequence, as determined by its DNA coding sequence, subsequent 
RNA processing, and translation. The secondary structure of a protein is defined by a series of 
local substructures, including α helices, β sheets, and turns. Stretches of unstructured and 
structured sections of the protein are strung together into an extended three dimensional 
structure, termed the tertiary structure. An array of forces holds these chains together, including 
hydrophobic interactions, hydrogen bonding, salt bridges, and disulfide bonding. These 
substructures frequently have local consequences on function, generating pockets of activity 
and interaction. Finally, the quaternary structure is comprised of complexes of proteins, which 
interact with one another in numerous ways to further diversify cellular functions.  
Protein-protein interactions, or PPIs, are as variable as the proteins that comprise them. 
However, overarching principles have been determined. Given their importance in the functional 
output of proteins,  PPI sites display stronger evolutionary conservation than non-binding sites in   3 
the protein sequence
3,4. The average size of a PPI site is 1600 ± 400 Å
2 5, although this range 
can vary widely from approximately 350 – 4750 Å
2 6. Importantly, the entirety of the interaction 
surface is not required for binding. Mutational analyses have identified a number of “hot spot” 
residues that contribute disproportionately to the interactionʼs binding affinity
3,4. These hot spots 
tend to cluster near the center of the PPI surface and are surrounded by a ring of residues of 
more flexible content. These surrounding residues frequently occlude the local solvent from the 
core interaction
7.  
Hot spot residues have diverse character. Hydrophobic patches often create greasy 
binding surfaces for interaction
8, with an increase in aromatic (histidine, tyrosine, phenylalanine, 
and tryptophan) and aliphatic residues (leucine, isoleucine, valine, and methionine) observed at 
the interface
5. Amino acids with hydrogen bonding capacity are frequently critical residues, with 
67% of hot spot residues participating in hydrogen bonding with the partnering protein (as 
opposed to 30% of non-hot spot residues)
4. While most charged residues are less prominent on 
the interaction face, electrostatic interactions can contribute to binding affinity, albeit less 
frequently
5,9. Finally, all of the hot spot residues are more tightly packed than those not involved 
in interaction
3,5, indicating the narrow margin for error on the PPI surface. 
 
Probing and targeting protein-protein interactions 
Prior to the completion of the Human Genome Project, the total number of predicted 
human genes climbed to greater than 100,000. This number has since been amended to 
20,000-25,000 genes
10, with the human proteome numbering around 20,000 proteins
11. Of 
these 20,000 proteins, there are an estimated 3,000 that are deemed “druggable” with 
conventional therapeutics, based upon similarity to targets already drugged successfully
12. This 
accounts for about one-quarter of known disease-driving drug targets
12, leaving several 
thousand desirable targets “undruggable.” Given the importance of PPIs in both normal and   4 
diseased cellular settings, this number would decrease significantly if protein-protein interactions 
were tractable targets. However, such targeting has proven difficult for the larger, more 
featureless nature of PPI surfaces. Nevertheless, a variety of modalities have been investigated 
for targeting PPIs, including small molecules, antibodies, and peptide mimetics. 
 
Small molecules 
It has historically been difficult to target protein interaction surfaces with small molecules, 
primarily because PPIs are much larger than typical small molecule-protein interaction surfaces 
(1600Å
2  as compared to 300-1000Å
2)
5,13. Given their size, small molecules are frequently more 
adept at binding deep grooves or pockets, features which are atypical of PPIs. In addition, 
existing small molecules serve as ineffective screening libraries for PPI targeting. In general, 
these libraries are biased for low molecular weight compounds that target common enzymatic 
binding clefts, such as protein kinase active sites
1. Despite these limitations, several molecules 
have been developed which can selectively perturb PPIs. 
•  p53, the “guardian of the genome”
14, is the most frequently mutated or deleted gene in 
human cancers
15. However, wildtype p53 can also be thwarted by upregulation of the 
proteins MDM2 and MDMX, which bind to p53 and prevent its transcriptional functions 
and target it for degradation
16. Structural analyses of this interaction identified a short 15-
amino acid domain of p53 which bound to a deep hydrophobic pocket on MDM2. Three 
hot spot residues (F19, W23, and L26) were shown to be particularly important for the 
interaction
17. This finding suggested that it might be feasible to find a small molecule 
which could target this subset of residues in a well-defined groove. Screening of a library 
of synthetic chemicals led to the discovery of a family of molecules that could disrupt the 
p53-MDM2 interaction with IC50 values between 100 and 300 nM
16. Further optimization 
identified one molecule, Nutlin-3a (IC50, 90nM), a potent analog that restores p53   5 
function and displays efficacy in a mouse model of sarcoma. Nutlin-3 molecules have 
provided a blueprint for next-generation designs of MDM2 and MDMX inhibitors. 
•  Human papillomavirus (HPV) is responsible for an array of disease manifestations, 
spanning harmless warts to malignant tumors
18. The small genome of this virus encodes 
two proteins, E1 and E2, whose interactions enable the continued replication of viral 
DNA. High throughput screening identified a lead molecule with an IC50 of 350 nM in an 
in vitro disruption assay
18. Additional optimization enhanced the potency nearly 40-fold
19. 
In this case, no structural information was available to direct optimization. 
•  Interleukin-2 (IL-2) receptors reside on the cell surface of T cells, signaling the cells to 
grow and divide upon engagement by the IL-2 ligand
20,21. Recombinant IL-2 has been 
used to restore immune system function in a variety of disease states
21, and antibodies 
used to disrupt the IL-2/IL-2R interaction are clinically effective as immunosuppressive 
therapy
21. Structural studies led to the development of small molecule antagonists of the 
IL-2/IL-2R interaction with an IC50 of 3 µM
22. Additional fragment-based medicinal 
chemistry efforts resulted in a 50-fold improvement in efficacy in vitro and modest effects 
in short-term cellular assays
23. 
•  The BCL-2 family of proteins regulates the intrinsic pathway of apoptosis, and members 
of the anti-apoptotic class of this family are frequently upregulated in cancer
24,25. In 2005, 
Abbott Laboratories performed a fragment-based NMR screen against the canonical 
interaction pocket of BCL-XL, an anti-apoptotic member of the BCL-2 family
26. The lead 
compound, ABT-737, binds three anti-apoptotic proteins BCL-2, BCL-w, and BCL-XL with 
high affinity (Ki ≤1 nM) and displays potent single agent efficacy in a series of cancer cell 
lines. Treatment with the molecule led to complete regression of tumors in a xenograft 
model of small cell lung cancer. In addition, ABT-737 also shows strong synergistic 
effects with clinical chemotherapeutic agents in a variety of cancer models. This   6 
molecule has since been further optimized for reduced serum binding and is in Phase I/II 
clinical trials for small cell lung cancer and hematologic malignancies
27. 
 
Antibodies 
The use of antibodies for targeting proteins or PPIs is an attractive strategy, since they 
are natureʼs solution to the challenge of binding large and flat surfaces. While antibodies have 
the therapeutic benefit of being highly specific for their intended target, they have proven difficult 
to use due to their poor oral bioavailability and immunogenic side effects
21. Additionally, 
antibodies fail to penetrate the cellular membrane, and thus their targets are limited to those on 
the exterior or surface of the cell. Nevertheless, early technical challenges have been overcome 
(e.g. humanized monoclonal antibodies), and antibodies now represent one of the most rapidly 
growing classes of novel drugs, with 17 antibodies approved for clinical use to date
28.  
Perhaps the most famous example of a therapeutic antibody is Herceptin, which is used 
for the treatment of HER2-positive metastatic breast cancer. HER2 is a transmembrane receptor 
tyrosine kinase which, upon dimerization, promotes cellular proliferation and survival through the 
RAS-MAP kinase pathway
29. Aberrant dimerization can result from receptor overexpression or 
mutagenesis, as is often observed in metastatic breast cancer, leading to abnormally high levels 
of cellular growth
30. Herceptin blocks HER2 dimerization and the resultant signaling cascade, 
leading to tumor regression
29. Since its introduction into the clinic almost 20 years ago, it has 
become one of the standards of care for HER2-positive breast cancer. 
 
Alpha-helical peptide mimetics 
Alpha helices commonly mediate PPIs, participating in 40% of homodimeric interfaces 
and 26% of heterodimeric interfaces
31. The prevalence of this interaction makes α-helical 
peptides an attractive option as dominant negative regulators of PPIs. As such, one could   7 
generate peptides consisting of the relevant amino acid sequence to serve such a purpose; 
however, outside the constraints of the protein infrastructure, short peptides do not typically 
maintain their native α-helical shape. In addition, the loss of secondary structure renders such 
peptides susceptible to proteolytic degradation. This combined with the cell impermeability of 
most peptides have limited their therapeutic use. A variety of methods have been developed to 
synthesize modified peptides that recreate the natural structure or binding surface of the 
interacting α-helix. 
One approach is to produce molecules that differ in the naturally observed chemical 
backbone of a protein. Peptoids are one example of this, in which the R group of each amino 
acid is shifted from the α-carbon to the backbone nitrogen
32. While these molecules do not 
necessarily form α-helices (in fact, the loss of CO    HN intrapeptide bonds may discourage 
it), they are more proteolytically stable due to the protected nitrogen in the backbone
32. Other 
alterations have been attempted in the peptide backbone, including urea peptidomimetics and 
peptidosulfonamides
33. Some success has been observed by substituting β-amino acids in 
place of the more common α-amino acids, generating β-peptides. These amino acids have more 
inherent α-helical character and are more proteolytically stable due to a more rigid backbone.
34 
More directed attempts to restore α-helical character have involved changes at the α-
carbon or R groups of the amino acids. The insertion of glutamate/lysine pairs one α-helical turn 
apart (i,i+4) can form stabilizing salt bridges in short peptides
35, and the insertion of two 
histidines at the i,i+4 positions can similarly stabilize α-helical structure
36.  The formation of 
covalent bonds through lactams
37 or disulfide interactions
38 between residues one or two α-
helical turns apart (i,i+3; i,i+4; i,i+7) can nucleate α-helicity. Finally, α, α-disubstitution at the α-
carbon has also been found to induce α-helicity
39.   8 
To date, the most advanced method of generating stabilized α-helical peptides is the 
formation of “stapled” peptides. In 1998, Grubbs and colleagues developed a system in which 
non-natural amino acids with terminal olefins (L-serine and L-homoserine O-allyl ethers) were 
inserted into a peptide sequence at i,i+4 positions
40. These olefins were methathesized using a 
ruthenium catalyst, generating a closed ring holding the residues together. At this stage, there 
was little evidence that this crosslinking strategy enhanced the α-helicity of the peptide. 
Two years later, Schafmeister et al. further developed this technique by screening a 
variety of all-hydrocarbon non-natural amino acids, sampling alternative sites of insertion, 
stereochemistry (R vs. S), and crosslinker length
41. An α-methyl group was installed on the α-
carbon along with the non-natural R group to further nucleate helicity. The α-helicities of these 
peptides were evaluated using circular dichroism, demonstrating significantly enhanced α-
helical character (35-85% α-helical). Improved proteolytic stability of the peptides, evaluated by 
trypsin cleavage, was observed, likely due to both the increased structure of the peptide and the 
lack of labile atoms in the closed ring or “staple” (Figure 1-1). An α-helical domain of the BCL-2 
family member protein BID was the first functional stapled peptide. This domain, known as the 
BH3 domain, regulates interactions between BID and other members of the BCL-2 family, which 
together mediate the intrinsic pathway of apoptosis
42. The BID stapled peptide, termed BID 
SAHB for stabilized alpha-helix of BCL-2 domains, showed restored α-helical structure, 
protease resistance, and cell permeability. BID SAHB recapitulated the biological activity of BID 
protein, including the induction of cytochrome c release from intact mitochondria and activation 
of apoptosis in a number of cancer cell lines. In addition, BID SAHB suppressed tumor growth in 
a mouse xenograft model of human leukemia. Today, multiple iterations of stapled peptides 
have been used for a variety of purposes, including mechanistic studies and therapeutic 
applications (Table 1-1). 
   9 
Figure 1-1 
 
Schematic of chemical stapling technique. Unstructured short peptides typically have little 
intrinsic shape, are proteolytically unstable, and are not cell-permeable. Introduction of two non-
natural amino acids with olefinic side chains allows for chemical crosslinking of spatially 
adjacent residues using a ruthenium-based catalyst. Such “stapling” can restore α-helical shape 
and confer protease resistance and cell permeability. 
   10 
Table 1-1: Published stapled alpha-helical peptides 
Stapled Peptide  Function  Reference 
BAD SAHB  Mechanistic studies of BADʼs role in apoptosis 
and the regulation of glucose metabolism 
Walensky, Mol Cell, 2006
43 
Danial, Nature Med, 2008
44 
BAX SAHB  Dissection of BAX propagation mechanism  Gavathiotis, Mol Cell, 
2010
45 
BID SAHB  Targeting of anti-apoptotic BCL-2 family 
proteins; in vivo efficacy in human leukemia 
mouse xenografts 
Walensky, Science, 2004
46 
Walensky, Mol Cell, 2006
43 
fStAx-35  Blocks TCF binding to β-catenin, interfering 
with canonical Wnt transcriptional activity 
Grossmann, PNAS, 2012
47 
MCL1 SAHB  Selective inhibitor of MCL1  Stewart, Nature Chem Bio, 
2010
48 
NPY-S1, -S2  Anticonvulsant neuropeptides that agonize 
neuroreceptors in the brain; suppress seizures 
in mouse model of epilepsy 
Green, Bioorg Med Chem, 
2013
49 
NYAD1  Inhibits capsid particle assembly of HIV  Zhang, J Mol Bio, 2008
50 
S1A10, S2A10  Apolipoportein mimetics that cause cholesterol 
efflux from cells by targeting ABCA1 
transporter 
Sviridov, Biochem Biophys 
Res Commun, 2011
51 
SAH-BCL-9  Disrupts β-catenin/BCL-9 interaction and 
resulting downstream Wnt transcriptional 
activity; in vivo efficacy in human colorectal 
carcinoma and myeloma mouse xenografts 
Takada, Sci Trans Med, 
2012
52 
SAH-gp-41  Inhibits fusion of HIV with extracellular 
membrane; double stapled and orally 
bioavailable 
Bird, PNAS, 2010
53 
SAH-p53-8  Disrupts inhibitory p53-MDM2 and –MDMX 
interactions and restores the p53 
transcriptional program  
Bernal, J Am Chem Soc, 
2007
54 
Bernal, Cancer Cell, 2010
55 
SAHM1  Mastermind peptide that disrupts Notch 
transcriptional complex; in vivo efficacy in T-
ALL mouse xenograft 
Moellering, Nature, 2009
56 
SP1-6  Bind at the co-activator protein binding site of 
the estrogen receptor 
Phillips, J Am Chem Soc, 
2011
57 
 
 
 
 
 
 
   11 
Summary 
A proteinʼs function is intimately related to its structure, often dictating its protein 
interactions, localization, enzymatic activity, and susceptibility to degradation. Few proteins act 
entirely alone, and a proteinʼs structure also dictates the library of molecules (nucleic acids, 
carbohydrates, other proteins) with which it can interact. The study of protein-protein 
interactions has advanced both a mechanistic understanding of cellular biology and approaches 
for therapeutic intervention. While traditional methods for targeting protein-protein interactions 
exist (e.g. small molecules and biologics), such approaches are limited due to the larger, flatter 
surfaces of protein-protein interactions and their intracellular location. Small peptide α-helical 
mimetics, representative of a common interaction motif at protein-protein interfaces, may serve 
as dominant negative agents for such interactions. Stapled α-helical peptides, developed in 
2000 by Schafmeister et al.
41, have proven to be valuable tools for both dissecting molecular 
pathways and developing prototype therapeutics. 
 
II. Apoptosis and the BCL-2 family 
  Cells are perpetually presented with three life choices: proliferation, maintenance, or 
death. The delicate balance between these three choices ensures a healthy organism, allowing 
for a steady supply of new cells or disposal of excess or injured cells, as the needs arise. The 
first identified form of programmed cell death, called apoptosis, is the cellʼs primary mechanism 
for “controlled cell deletion”
58. It is conserved through all multicellular eukaryotes
59, and gain-or 
loss-of-function in this pathway leads to disease. 
 
Apoptosis 
  The loss of cells in living organisms was documented in the late 1960s
60-62, but it wasnʼt 
until 1972 that the term “apoptosis” was coined
58. This form of programmed cell death occurs   12 
throughout normal embryonic development and in healthy adult tissues, clearing away 
unnecessary or damaged cells. In disease states, this process is often deregulated. Too much 
apoptosis results in degenerative diseases, immunodeficiency, and infertility, while too little 
apoptosis leads to cancer or autoimmunity
59. Apoptosis can be induced by a variety of stimuli, 
including developmental signals
63, DNA damage
64, growth factor deprivation
65,66, anoikis
67, and 
oncogene activation
68,69. Morphologically, apoptosing cells undergo nuclear condensation, DNA 
fragmentation, membrane blebbing, and cell shrinkage
70, producing distinct diagnostic cellular 
phenotypes for experimental study. 
  Some of the earliest and most elegant studies to understand the biological basis for 
apoptosis came from the C. elegans research community in the 1980s. The fate of all cells in 
the nematode was meticulously traced from the beginning of development, and it was noted that 
a subset of cells always died at predictable times. Robert Horvitz and colleagues decided to 
mutagenize the worms to elucidate the relevant genes, and what emerged were the earliest 
known apoptotic genes. Ced-3 and ced-4 were shown to be pro-apoptotic factors required for 
cell death, while ced-9 had an anti-apoptotic, protective phenotype
71,72. These genes have since 
been shown to have homologues throughout all metazoans and are thus fundamental cellular 
regulators. 
  Apoptosis proceeds through the activity of enzymes called caspases. Caspases are 
produced as an inactive pro-caspase, which following proteolytic processing, associates into 
dimers to form the active enzyme
41,73. The active enzyme is a cysteine protease that cleaves 
conserved amino acid sequences following an aspartic acid residue. Caspases can be sorted 
into two categories: initiator and effector caspases. Initiator caspases, usually capable of self-
cleavage and activation, recognize and expand the initial apoptotic signal. Effector caspases, 
which require initiator caspases for activation, carry out the apoptotic events
59 by cleaving 
proteins necessary for cell life and disassembling cellular substructures. For example, caspase-  13 
3 cleaves I
CAD, which is an inhibitor of the nuclease responsible for DNA fragmentation
74, and 
caspase-6 cuts nuclear lamins
75. Together these cleavage reactions produce the observed 
chromatin condensation characteristic of apoptotic cell death.  
  Apoptosis can be carried out by two pathways: the extrinsic pathway and the intrinsic 
pathway. The extrinsic pathway is initiated through binding and activation of transmembrane 
proteins of the death receptor family (ex. FAS
76 and TNFR-1)
77,78. Activation of these proteins 
results in the formation of the death-inducing signaling complex (DISC), comprised of FADD
79 
and procaspases-8 and -10
76,80. Procaspases-8 and -10 self-cleave due to induced proximity, 
followed by subsequent activation of downstream effector caspases. Additionally, caspase-8 
can further amplify the apoptotic signal by cleaving BID to tBID
81,82, which engages the intrinsic 
pathway of apoptosis. 
  The intrinsic pathway is initiated by a wide variety of cellular stressors, including DNA 
damage, oxidative stress, cytosolic calcium ion overload, and ER stress
80. These signals 
activate the BCL-2 family of proteins (discussed in detail below) to induce mitochondrial outer 
membrane permeabilization (MOMP). MOMP allows the release of cytochrome c
83,84 and other 
apoptogenic factors into the cytosol, where cytochrome c, apoptotic protease activating factor 
(APAF-1), and procaspase-9 assemble to form the apoptosome
85. The apoptotsome then 
activates procaspase-9, which further cleaves downstream effector caspases such as caspase-
3 and -7. 
  Should apoptosis be activated in error, a variety of proteins exist to inhibit the activated 
pathways. Unlike caspase-8, FLIPs (FADD-like ICE inhibitor proteins) bind available FADD 
cofactor but lack the essential catalytic residues to cleave downstream targets
86,87. IAPs 
(inhibitors of apoptosis proteins) directly inhibit the effector caspases-3 and -7
88. However, in 
most cases, once the onslaught of caspase activation begins and the mitochondria are 
compromised, apoptosis proceeds.   14 
 
The BCL-2 family of proteins 
  The intrinsic pathway of apoptosis is tightly regulated by members of the BCL-2 family of 
proteins, which carefully control the induction or repression of mitochondrial outer membrane 
permeabilization (MOMP). The founding member of the family, BCL-2 (B-Cell Lymphoma 2) was 
discovered in the 1980s as an oncogene of unknown function activated by a chromosomal 
translocation in human lymphomas
24,89,90. Further studies showed that overexpression of the 
gene product led to increased cell survival and tumorigenicity
91-93 without influencing levels of 
cellular proliferation
91. Since that time, BCL-2 family members have become well-established as 
mediators of the intrinsic apoptotic pathway,
 with evolutionary conservation in a wide variety of 
organisms
72,94,95 and key roles in a broad array of human diseases. For example, the anti-
apoptotic BCL-2 proteins MCL-1 and BCL-XL are two of the most frequently upregulated genes 
across all human cancers, while the pro-apoptotic BCL-2 proteins BOK and PUMA are 
commonly deleted
25.  
BCL-2 proteins are divided into three subclasses based on function and sequence 
homology
96,97 (Figure 1-2). The four regions of sequence homology are known as the BH (BCL-
2 Homology) domains. Multidomain proapoptotic proteins contain BH domains 1-3 and include 
members BAX, BAK, and BOK. Upon induction of apoptosis, these death-promoting proteins 
localize to the mitochondrial membrane
98 and oligomerize to form pores
99, resulting in MOMP. 
Cytochrome c diffuses through these pores into the cytosol
100, activating downstream caspases 
and the apoptotic cascade
101. Simultaneous deletion of Bax and Bak in mice severely impairs 
normal development, while generating lymphocytes highly resistant to apoptotic stimuli
102. In 
contrast, the antiapoptotic proteins (e.g. BCL-2, BCL-w, and BCL-XL) contain BH domains 1-4 
and function to promote cellular survival
91-93,103,104. Finally, the proapoptotic BH3-only proteins  
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Figure 1-2 
 
Walensky, CDD, 2006 
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The BCL-2 family of apoptotic regulators can be separated into three families.  
Antiapoptotic BCL-2 proteins share BCL-2 homology (BH) domains 1-4 and serve a pro-survival 
function. Proapoptotic BCL-2 proteins are further subdivided into two classes. The multidomain 
proapoptotic proteins share BH domains 1-3 and carry out the final steps of mitochondrial 
permeabilization. The BH3-only proteins contain only the third BH domain and relay signals of 
cellular stress to other family members.   16 
contain only the BH3 domain and respond to a variety of stimuli to induce apoptosis, including 
cytokine withdrawal
105, calcium ion flux
105, DNA damage
106, and infrared radiation
107. 
Two major models have been proposed to explain the manner in which these three 
classes of BCL-2 family members interact to regulate the induction of apoptosis. In the first 
model, known as the “direct activation” model
108,109, BH3-only proteins are divided into two 
classes: activators, which can bind directly to proapoptotic proteins, and sensitizers, which can 
bind only to antiapoptotic proteins. Apoptosis results from the binding of the BH3 domains of 
activators to BAX and BAK, causing BAX and BAK to permeabilize the mitochondrial membrane 
and activate the downstream apoptotic pathway. In healthy cells, this process is prevented by 
the presence of antiapoptotic factors which can sequester incoming BH3-only proteins. 
Apoptosis is activated only when sufficient levels of BH3-only proteins are present to saturate 
the antiapoptotic factors. Free activators are then able to bind directly to the death proteins, 
triggering the apoptotic cascade. 
In contrast, in the “indirect activation” model
110,111, BAX and BAK are in a constitutively 
active state, blocked only by repressive binding of the antiapoptotic proteins. In this model, all 
BH3-only proteins bind only to antiapoptotic proteins. Apoptosis is activated when BH3-only 
proteins bind to the antiapoptotic proteins and trigger their release from the death proteins. The 
uninhibited death proteins are now able to permeabilize the membrane, causing the activation of 
apoptosis. Understanding how this family of proteins works together to respond properly to the 
cellular environment remains an active area of investigation. 
 
p53 upregulated modulator of apoptosis (PUMA) 
PUMA (p53 Upregulated Modulator of Apoptosis) belongs to the BH3-only class of the 
BCL-2 family and acts to promote the induction of apoptosis. Puma was first characterized as a 
transcriptional target of p53, showing rapid up-regulation upon p53 stimulation
112-114. PUMA was   17 
found to share functions with other BCL-2 family members, including localization to the 
mitochondrial membrane, the ability to induce the release of cytochrome c from mitochondria, 
and the capacity to initiate apoptosis in human cells. Puma
-/- cells are less sensitive to a variety 
of both p53-dependent and independent insults, including irradiation, cytokine withdrawal, 
hypoxia, and DNA-damaging agents
106,107,115. While Puma
-/- knockout mice show little phenotype 
of their own, 50% of Puma
+/-/Bim
-/- mice develop lymphomas, in comparison to only 20% of Bim
-
/- mice
116. This implies that PUMA and BIM have overlapping but distinct functions. In addition to 
its role at the mitochondria, PUMA is necessary for the induction of ER stress-induced 
apoptosis
117,118. Together, these data highlight the importance of PUMAʼs role in the regulation 
of apoptosis, both on its own and in conjunction with other BH3-only proteins. However, the 
mechanism by which PUMA induces apoptosis remains controversial.  
As outlined above, the direct activation model divides the BH3-only class of proteins into 
broad categories: direct activators and sensitizers. While BIM
119,120 and BID
43 are accepted as 
direct activators, the role of PUMA as either a direct activator or a sensitizer remains unclear. 
Evidence to support PUMA as a direct activator comes from studies of both the PUMA BH3 
domain and the full-length protein, in which the PUMA BH3 domain is shown to physically 
associate with and activate BAX
121-125. This experimental evidence suggests that PUMA, like 
BIM and BID, may also directly activate BAX and BAK to induce apoptosis.  
In contrast to this work, however, several groups have published evidence suggesting a 
role for PUMA exclusively as a sensitizer BH3-only protein. Attempts to characterize the BCL-2 
family binding partners for PUMA have uniformly shown PUMA to be a pan-antiapoptotic binder 
126-128; however, the association between PUMA and BAX or BAK has proved difficult to 
confirm
129,130. The discrepancies between these studies and those suggesting direct activation 
may result from the transient nature of a PUMA-BAX interaction or the lack of structure of the   18 
PUMA BH3 peptides used. These contradictions necessitate further study of PUMA and its role 
in BAX/BAK activation. 
 
PUMA and neuroblastoma 
While BH3-only proteins frequently overlap in function
131, it is clear that some stress 
stimuli or cell types engage the pro-apoptotic function of some BH3-only proteins more than 
others. While PUMA broadly acts as a downstream effector of p53-driven apoptosis, it has also 
been show to have more selective roles in the activation of neuronal and neural precursor cell 
apoptosis. In particular, activation of apoptosis by proteasomal inhibitors
132, oxidative stress
123, 
or DNA damaging agents
133,134 in cells of neuroectodermal origin was dependent on the 
presence of PUMA. Interestingly, a study by Reimertz et al. in the human neuroblastoma SH-
SY5Y cell line identified PUMA as the top upregulated pro-apoptotic gene following induction of 
ER stress and the ensuing apoptotic response
118. Overexpression of PUMA in these cells was 
sufficient to induce apoptosis, suggesting that a PUMA mimetic could serve a therapeutic 
function in neuroblastoma cells. 
 
Structural interaction of multidomain pro-apoptotics and BH3-only proteins    
  The first high resolution structure of a member of the BCL-2 family was that of BCL-XL. 
This anti-apoptotic protein was structurally defined by a series of α-helices, two which were 
highly hydrophobic and localized at the core of the protein, surrounded by external amphipathic 
helices. Notably, three of the four conserved BCL-2 homology domains were spatially adjacent, 
forming a deep hydrophobic cleft
135. This cleft was determined to be the site of interaction for 
binding the BH3 domain of the proapoptotic protein BAK
136, suggesting a mechanism by which 
anti-apoptotic proteins sequester pro-apoptotic proteins and thereby block their function. This   19 
paradigm has held for the BH3 interactions of all proapoptotic proteins, both multidomain and 
BH3-only, to the anti-apoptotics proteins.  
  Based on the sequence similarity of the multidomain proapoptotics BAX and BAK with 
the antiapoptotic proteins, it has been hypothesized that if BH3-only proteins could in fact bind 
to BAX or BAK, the binding would occur in the same hydrophobic pocket. In an effort to resolve 
this question, NMR studies were performed with a stabilized version of the BH3 domain of BIM 
(BIM SAHB) and full-length BAX
119. Surprisingly, rather than binding to the canonical 
hydrophobic groove, BIM SAHB bound to a more shallow hydrophobic binding site on the 
opposite face of the protein consisting of overlapping α-helices 1 and 6 (Figure 1-3). This new 
binding site was shown to be the site of direct activation of BAX by the BIM BH3 domain, and 
was thus named the “trigger site.” This trigger site has since been the target of therapeutic 
development aimed at lowering the apoptotic threshold in cancer and other diseases of 
pathologic cellular excess
137.  
Until recently, similar structural studies were difficult to perform on BAK, due to the 
challenge of producing full-length recombinant protein. However, recent work by Leshchiner et 
al. successfully generated a mutated version of full-length BAK that is amenable to large-scale 
recombinant protein production and purification
138. To investigate the binding of BH3-only 
proteins on BAK, crosslinkable peptides of the BH3 domain of BID were incubated with the full-
length recombinant BAK. Interestingly, these peptides bound exclusively to the canonical 
hydrophobic pocket, analogous to the binding of the BH3 domain on antiapoptotic proteins. 
Binding at this site caused activation of BAK in a variety of assays. These findings suggest that 
there may be two mechanisms of activation for the executioner proteins by the BH3-only class 
of proteins, one for cytosolic BAX and another for membrane-integrated BAK and perhaps BAX. 
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Figure 1-3 
	 ﾠ
Gavathoitis, Nature, 2008 
 
BIM SAHB directly binds BAX in a site directly opposite the canonical BH3 binding 
groove. On a structure of full-length BAX, the canonical binding groove, analogous to the BH3 
binding groove on anti-apoptotic proteins, is shown in red, with the C-terminal α-helix 9 inserted 
into the groove of inactive BAX. The identified “trigger site” for BIM SAHB binding and activation, 
located on the opposite side of the protein, is shown in orange. 
	 ﾠ
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Summary 
  An organismʼs ability to carefully regulate the life and death of its cells is critical for 
growth and survival. Apoptosis, a form of programmed cell death, allows for the controlled 
destruction of unnecessary or deleterious cells, a process partially regulated by the BCL-2 
family of proteins. Importantly, the BCL-2 family carefully integrates signals of cellular stress at 
the outer membrane of the mitochondria, where a balancing act between pro- and antiapoptotic 
proteins dictates the cellular outcome. Our understanding of the interactions among these 
proteins has grown enormously in the last two decades, providing novel opportunities for 
therapeutic targeting. 
 
III. Transcription factor targeting 
Transcription factors are fundamental regulators of cellular homeostasis, modulating with 
exquisite precision the timing and rate of gene expression. Despite their established pathogenic 
role in the development, progression, and maintenance of cancer
139, deregulated transcription 
factors have long been deemed “undruggable” due to the difficulty of targeting protein-protein 
and protein-DNA interactions, particularly within the nucleus. New pharmacologic strategies, 
including nucleic acid mimetics
140 and stabilized peptides
52,54,56, have reinvigorated efforts to 
address these formidable targets.  
 
Overview of transcription factor targeting 
  Many of the most notorious oncogenes in cancer biology, such as RAS, AKT, and BCR-
ABL, are protein kinases. These overactive, deregulated kinases ramp up the cellular signaling 
pathways that instruct a cell to grow, divide, and migrate. These proteins are also some of the 
most attractive targets from a therapeutic perspective. ATP binds to the vast majority of protein 
kinases through a deep hydrophobic cleft
141, providing an amenable site for traditional small   22 
molecule targeting. Indeed, well-known cancer therapeutics including Imatinib (better known as 
Gleevec), Sunitinib, and Erlontinib all target a spectrum of protein kinases. Unfortunately, 
kinases represent only a small portion of known oncogenes. However, many of these kinase-
driven signaling pathways converge on a smaller number of transcription factors, which serve as 
distinct nodes of regulation that can amplify diverse cellular signals: transcription factors.  
There are three main classes of transcription factors important in human cancer
139. In 
the first class, steroid receptors like estrogen and androgen receptors move to the nucleus and 
induce transcription upon binding of their respective ligands. A second class resides in the 
nucleus constitutively and become active only upon signaling from upstream kinase cascades. 
These resident nuclear proteins include c-JUN, E2F, and MYC. Finally, a third class of 
transcription factors are normally cytosolic and only move into the nucleus when a signal is 
received to activate transcription. Proteins like the STAT family and NF-kB fall into this group. 
While these three classes of transcription factors all function in slightly different 
manners, their basic route to transcriptional output follows a similar path: nuclear localization, 
activation, association with co-factors and DNA binding, and transcription of downstream gene 
targets. Each of these steps offers possibilities for therapeutic targeting. Thus far, attempts have 
been made to modulate transcription factor activity with decoy oligonucleotide binding sites
142, 
DNA-binding sequence-specific polyamides
143, zinc finger nucleases
144, interfering RNA
145, and 
small molecules
146.  Additionally, many groups have made use of short, stabilized peptides 
(discussed in detail above) to disrupt interactions between transcription factors and other 
regulatory proteins, two examples of which are presented below.	 ﾠ	 ﾠ
•  The protein Notch is a transmembrane protein that sits on the extracellular 
membrane. Ligand binding to the extracellular portion of the protein results in 
proteolytic cleavage of the receptor by γ-secretase, causing the release of an 
intracellular fragment called ICN1. ICN1 translocates to the nucleus, where it   23 
engages two additional proteins, CSL and Mastermind (MAML). This complex is 
now sufficient to recruit core transcriptional machinery to activate Notch-
dependent target genes
147. Previously devised therapies include small molecule 
inhibitors of γ-secretase
148, but these molecules have a variety of off-target 
effects. In an effort to specifically target Notch, work by Moellering and 
colleagues examined known structures of the ICN1-CSL-MAML complex. 
Notably, an α-helical portion of MAML binds to a long groove formed by the 
juncture of ICN1 and CSL. Stapled peptides generated against this α-helical 
region inhibited formation of the ICN1-CSL-MAML complex, effectively turning off 
NOTCH-dependent transcription
56. This peptide also showed in vivo efficacy in a 
mouse model of T-ALL. 
•  Myc (c-Myc, N-Myc, and L-Myc) is broadly expressed throughout development 
and in a subset of adult cells, regulating cellular proliferation, differentiation, and 
apoptosis
149. A basic-helix-loop-helix leucine zipper (bHLH LZ) protein, Myc 
carries out its transcriptional activities through dimerization of its bHLH LZ region 
with the bHLH LZ region of its partner protein, Max. Notably, Myc is one of the 
mostly commonly overexpressed oncogenes in human cancers
25. Despite this, 
there has been much hesitation about targeting Myc, due to its importance to 
normal and cancer cells alike. Additionally, it was unknown whether therapeutic 
modulation of Myc would be beneficial only to those tumors initially driven by 
Myc, or if it could also influence cancers of different origins. To address these 
questions, Soucek et al. generated an inducible, dominant negative form of Myc, 
termed “omoMyc”
150. This mutant was installed into a preclinical mouse model of 
Ras-induced lung cancer, and both the therapeutic benefits and side effects were   24 
monitored. Amazingly, upon induction of omoMyc, Ras-driven lung tumors 
disappeared. Additional effects were observed in other rapidly proliferating 
tissues (skin and bone marrow, for example), but these side effects were found to 
be completely reversible. 
Myc inhibition has been approached in a number of ways, including both 
direct
151,152 and indirect
153 small molecule inhibition and short peptide 
inhibition
154,155. These short peptides have targeted Mycʼs dimerization domain, 
which is predominantly made of two adjoined α-helices. However, none of these 
approaches have yet translated from the laboratory to the clinic.  
 
Basic helix-loop-helix proteins 
  One of the largest classes of transcription factors is the basic helix-loop-helix (bHLH) 
family. These proteins are defined by the presence of an amino terminal basic region, followed 
by two amphipathic α-helices joined together by a small loop region
156-158. bHLH proteins are 
critical for a variety of developmental processes throughout the tissues of an organism, including 
hematopoietic cells, cardiac muscle, skeleton, and both the peripheral and central nervous 
systems, and are of particular importance to the determination of cell-type specifications
159.  
The first members of the bHLH family were discovered in 1989 by comparison of a 
variety of transcription factors that all bound to a common DNA consensus sequence known as 
an E-box (5ʼ-CANNTG-3ʼ)
156. Phylogenetic analyses have shown that the bHLH family is both 
expansive and ancient, with over 500 bHLH factors present in animals, plants and fungi
160-163. 
The family can be divided into roughly 6 groups, based on specific E-box binding, conservation 
of residues in other parts of the bHLH motif, and the presence or absence of other domains
164. 
Class I proteins (eg. E12, E47) are expressed in many tissues, while Class II proteins (eg. 
OLIG2, NeuroD) show a more tissue-restricted localization. Class III proteins (eg. MYC, TFE3)   25 
are bHLH proteins with a leucine zipper motif just C-terminal to the bHLH, and Class IV proteins 
(eg. MAX, MAD) are those that can dimerize with Class III proteins. Class V proteins (eg. Id 
proteins) lack a basic region and therefore cannot bind to DNA, serving as cellular inhibitors of 
Class I and II proteins. Finally, Class VI proteins (eg. Hairy, Enhancer of split) are characterized 
by a proline residue in their basic region.  
It is now known that the conserved basic region of bHLH proteins binds to the major 
groove of DNA at an E-box sequence. In particular, a conserved glutamic acid in the basic 
region binds to the 5ʼ-CA-3ʼ nucleotides of the E-box, while other residues in the basic region 
dictate specificity for various E-boxes
160. For instance, a mutation in the basic region of the 
bHLH factor MyoD (L14R) alters the binding specificity for the protein from its traditional 
sequence (5ʼ-CAGCTG-3ʼ) to that of c-Myc (5ʼ-CACGTG-3ʼ)
165.  
  The second structural region of the domain, the helix-loop-helix region, allows for 
dimerization of these proteins
157. Structural analyses have determined that these two α-helices 
dimerize in a parallel orientation
166,167, coiling around each other in a handshake pattern. In 
bHLH leucine zipper proteins (for instance, the proteins Myc and Max), the second α-helix is 
followed by a leucine zipper α-helical motif, increasing the region and specificity of dimerization. 
Dimerization is dependent upon the ability of α-helical pairings to line up in correct register with 
one another, placing hydrophobic residues adjacent to one another and allowing for the 
formation of stabilizing salt bridges
167,168. bHLH proteins can form either homo- or heterodimeric 
pairs, and the choice of dimerization partners depends both on availability and sequence 
compatibility. This variability affords bHLH factor-driven transcription increased levels of 
flexibility and control. 
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The bHLH protein OLIG2 
  In 2000, a new family of bHLH transcription factors was discovered in a screen for bHLH 
proteins that are expressed in neural progenitor cells
169,170. Located only 40kb apart on 
chromosome 21 and aptly named Olig1 and Olig2 (and later joined by Olig3
171), both proteins 
are expressed during development of the central nervous system
172. Together, OLIG1 and 
OLIG2 are critical for the development of oligodendrocytes, with a limited amount of functional 
redundancy between them
169,170. OLIG2 alone is responsible for the differentiation of somatic 
motor neurons
170,171. Olig1
-/- knockout mice are viable and relatively normal, while Olig2
-/- 
knockout mice die at birth and have no motor neurons or mature oligodendrocytes
173-175. Taken 
together, these data suggest that while OLIG1 and OLIG2 each contribute to early 
neurodevelopment, OLIG2 clearly plays the predominant role. Additionally, in adults, OLIG2 
expression is restricted to neural progenitor cells in the subventricular zone, NG2-positive glia, 
and mature myelinating oligodendrocytes
172,176.  
  Initially in development, anti-neural bHLH proteins expand the pool of progenitor cells, 
until pro-neural factors take over and induce differentiation. In contrast, OLIG2 plays both anti-
neurogenic and pro-neurogenic roles during development. Early in development, OLIG2 
assumes an anti-neurogenic role, keeping cells in a replication-competent stage. Later in 
development, OLIG2 becomes pro-neurogenic, pushing cells to exit the cell cycle and 
differentiate into motor neurons and oligodendrocytes
169,170. The mechanisms by which OLIG2 
can perform these diverse functions are still somewhat unclear. As a bHLH protein, OLIG2 can 
both homodimerize and heterodimerize with other bHLH factors to bind DNA, a capacity 
dependent on the integrity of the bHLH domain
177. In some cases, OLIG2 is able to act as a 
transcriptional repressor. For example, expression of Olig2 decreases expression of both Hb9 
and p21
177,178. However, in other instances, OLIG2 can have a transcriptional activator   27 
function
179. These differences are likely dependent on other proteins that can complex with 
OLIG2 and affect its transcriptional control. 
  Like many proteins, OLIG2 is regulated by phosphorylation. Residues 77-88 of OLIG2 
are a series of consecutive serines and threonines, some of which have been shown to be 
phosphorylated in vitro
176. However, these phosphorylation events have yet to be identified in 
living cells. In contrast, phosphorylation of serine 147, located in Helix 2 of the bHLH domain, 
has been identified in embryonic mouse tissue and seems to direct OLIG2 function toward 
motor neuron specification
180. Additionally, phosphorylation of serines 10, 13, and 14 has been 
identified in mouse neurospheres and glioma cell cultures
181. Combined mutation of all three 
phosphorylation sites greatly reduces the proliferative impact of OLIG2, although it is still 
capable of inducing differentiation. This triple phosphorylation motif is also required for OLIG2ʼs 
ability to inhibit p53 activity. This offers a potential mechanism for the proliferation effect of 
OLIG2, a capacity hypothesized to partially account for OLIG2ʼs tumorigenic activity
181,182.  
 
OLIG2 and glioma 
  In addition to its developmental functions, OLIG2 also plays a more insidious role in 
tumorigenesis of the brain. While gliomas account for less than 2% of all new cancer cases 
each year, they are the third leading cause of cancer-related death in men and the fourth 
leading cause of death in women aged 15-34 years
183. Analysis of a variety of brain tumors has 
found that OLIG2 is expressed in 100% of diffuse gliomas, including astrocytomas, 
oligodendrogliomas, and oligoastrocytomas
184,185. OLIG2 marks a subset of the tumor cells that 
have stem cell-like qualities
178,186and are highly resistant to radiation and chemotherapy
187. 
  Importantly, in addition to serving as a marker for glioma stem cells, OLIG2 function is 
required for glioma formation in a mouse model
178. Mouse neurospheres with background 
mutations in Ink4a/ARF and EGFRvIII engineered to be Olig1
+/-/Olig2
+/- or Olig1
-/-/Olig2
-/- were   28 
injected into SCID mice, and the emergence of tumors was monitored. Strikingly, mice with at 
least one functional copy of Olig2 (but not Olig1) formed tumors within three months, while those 
without Olig2 remained tumor free for the length of the study (Figure 1-4). This dependence on 
OLIG2, as well as data suggesting that ablation of OLIG2 in adult mice is tolerable
188, makes 
OLIG2 and its transcriptional activities attractive targets for therapeutic intervention. 
 
Summary 
More than ten years ago, the basic helix-loop-helix transcription factors OLIG1 and 
OLIG2 were identified as the earliest known markers of oligodendrocyte precursor cells. A 
member of the basic helix-loop-helix (bHLH) transcription factor family, OLIG2 dimerizes 
through its bHLH domain in order to exert its transcriptional effects. OLIG2 is critical throughout 
development for the formation of somatic motor neurons and myelinating oligodendrocytes. In 
addition, it has a role in the proliferation of neural progenitor cells, with a pathobiological 
corollary in brain tumor growth. OLIG2 expression marks tumorigenic glioma stem cells and is 
required for the formation of gliomas in mouse models. Unfortunately, transcription factors have 
historically been resistant to therapeutic intervention due to the lack of deep binding grooves 
and the difficulty of targeting protein-DNA interactions in the nucleus. However, progress has 
recently been made in this area using novel techniques to disrupt protein-protein interactions, 
including the use of stapled peptides, reinvigorating efforts to target transcription factors in 
general and OLIG2 in particular. 
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Figure 1-4 
	 ﾠ
Ligon, Neuron, 2007 
 
Olig2 is required for the formation of gliomas in a mouse tumor model. (A) Olig1
+/-/Olig2
+/- 
or Olig1
-/-/Olig2
-/- Ink4a/ARF
-/- EGFRvIII neurospheres were generated and injected into the 
brains of SCID mice. (B) Kaplan-Meier survival analysis. While mice with at least one copy of 
Olig2 formed tumors within three months, mice with homozygous deletion for Olig2 remained 
tumor-free (96% survival at 273 days). (C) Restoration of Olig2 restored tumorigenic capacity. 
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Multimodal Interaction with BCL-2 Family Proteins Underlies  
the Pro-Apoptotic Activity of PUMA BH3 
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Abstract 
PUMA is a pro-apoptotic BCL-2 family member first discovered as a transcriptional 
target of p53 and has since been implicated in driving the apoptotic response to a diversity of 
p53-dependent and independent cellular insults. As such, deciphering the spectrum of PUMA 
interactions that confer its context-dependent pro-apoptotic properties remains a high priority 
goal. The BH3 interaction domain of PUMA is well known to broadly engage the diversity of anti-
apoptotic targets, but its ability to directly bind and activate pro-apoptotic effectors such as BAX 
remains unresolved. We generated PUMA SAHB, a structurally-stabilized PUMA BH3 helix that, 
in addition to targeting anti-apoptotic proteins, directly binds to BAX. Multidisciplinary analyses 
revealed that PUMA SAHB engages an α1/α6 trigger site on BAX, inducing its functional 
activation. Both PUMA SAHB and PUMA protein pull-downs confirmed interaction with native 
pro- and anti-apoptotic targets. As PUMA has been implicated in driving apoptosis in a variety of 
neuronal cell types, we further demonstrated the therapeutic potential of PUMA SAHB in 
neuroblastoma. Thus, PUMA BH3 is a dual anti-apoptotic inhibitor and pro-apoptotic direct 
activator, and its mimetics may serve as effective pharmacologic triggers of apoptosis in 
cancers of neural origin. 	 ﾠ 45	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Introduction 
     The cellular decision to live or die is controlled by members of the BCL-2 protein family, 
which executes the activation or suppression of mitochondrial apoptosis
1. BCL-2 proteins are 
classified into three groups based on sequence homology and function. Anti-apoptotic members 
such as BCL-2 contain up to four BCL-2 Homology (BH) domains, whereas the multidomain pro-
apoptotic proteins, including BAX and BAK, contain three BH domains. A heterogeneous group 
of proteins that contain only the BH3 motif function as afferent sensors of stress. These so 
called “BH3-only” proteins relay pro-apoptotic signals to the multidomain members, which 
ultimately render a life or death decision based upon the overall balance between the degree of 
stress and the anti-apoptotic reserve.  
PUMA (p53-Upregulated Modulator of Apoptosis) is one such BH3-only protein that was 
first identified as a transcriptional target of p53
2-4. p53 deletion and mutagenesis can effectively 
blunt PUMA upregulation, contributing to the pathogenesis, maintenance, and chemoresistance 
of human cancer; reconstituting PUMA function in this context can effectively reactivate 
apoptosis
4,5. Puma
-/- cells have since been shown to manifest reduced sensitivity to a variety of 
p53-dependent and independent insults, including irradiation, DNA-damaging agents, cytokine 
withdrawal, hypoxia, and endoplasmic-reticulum stress
4,6-10. These data highlight the importance 
of PUMAʼs role in apoptosis regulation in health and disease, and the potential of PUMA-based 
therapeutics to alternatively enhance chemo- and radiosensitivity in the context of cancer 
treatment and mitigate damage to host tissues through targeted PUMA inhibition
11. Thus, 
deciphering the spectrum of PUMA interactions that confer its context-dependent pro-apoptotic 
properties remains a high priority goal.   
     The BH3-only protein interaction circuit is believed to induce apoptosis by two 
complementary mechanisms. The first is by BH3-only protein-mediated “inhibition of the 
inhibitors” of cell death
12,13. That is, the BH3 motif of BH3-only proteins engages the canonical 	 ﾠ 46	 ﾠ
BH3-binding groove of anti-apoptotic targets to neutralize their capacity to bind and block the 
multidomain pro-apoptotic effectors BAX and BAK. In addition, select members of the BH3-only 
class of apoptotic proteins have been shown to directly bind and activate BAK and BAX at 
discrete canonical
14 and non-canonical
15 BH3-binding sites on these proteins, respectively.  
Whereas structural and biochemical data support direct and functional interactions for 
the BH3 domains of BIM and BID with BAX and BAK
15-18, the direct binding capability of the 
PUMA BH3 helix is unresolved. A series of studies that employed in vitro functional assays, and 
cellular and in vivo analyses, have yielded conflicting results regarding the existence and 
potential mechanistic role of direct PUMA interactions with BAX and/or BAK. A physical 
association between PUMA protein and BAX has been shown in bacterial two-hybrid assays
19, 
yeast cells
20, in vitro and mammalian cell co-immunoprecipitation studies
21-23, and by FRET 
analysis
23, indicating that the two proteins can interact. Puma
-/-Bim
-/-Bid
-/- knockout (TKO) mice 
show developmental defects that are reminiscent of, although perhaps less severe than
24, those 
observed in Bax
-/-Bak
-/- mice, suggesting that eliminating key direct activators may be 
tantamount to knocking out BAX and BAK altogether
25.  
However, a series of studies document that the pro-apoptotic activity of PUMA instead 
derives from exclusive anti-apoptotic inhibition, citing the lack of direct interaction between 
PUMA and BAX upon co-immunoprecipitation from cells exposed to discrete stress stimuli
13,26,27. 
In addition, a C-terminally truncated form of PUMA that manifests decreased BAX-binding 
activity retained pro-apoptotic potency equivalent to that of full-length PUMA, suggestive that the 
contribution of PUMA-BAX engagement, at least in this experimental context, was not 
essential
22. Such cellular analyses are made all-the-more challenging by the proposed “hit and 
run” nature of the transient interactions between direct BH3 activators and BAX/BAK, potentially 
confounding co-immunoprecipitation-based studies. Even liposomal release assays, which 
probe functional activation of BAX and BAK upon administration of discrete 	 ﾠ 47	 ﾠ
agonists/antagonists, have had mixed results with PUMA BH3
28,29. Thus, we undertook a 
biochemical, structural, and cellular study to interrogate the capacity of PUMA BH3 to directly 
and functionally engage BAX, and thereby contribute to its pro-apoptotic activity in vitro and in 
cells. 
 
Results 
Design, synthesis, and anti-apoptotic binding activity of hydrocarbon-stapled PUMA BH3 helices 
Whereas select BH3-only proteins, like BID, are highly structured and maintain an α-
helical BH3 domain in the unbound state, others are intrinsically disordered
30 but undergo α-
helical folding of the BH3 domain upon binding to compatible anti-apoptotic grooves
31. In 
dissecting the mechanism of BH3-mediated direct BAX activation, we determined that a helical 
BID or BIM BH3 peptide, but not unfolded ones, were capable of engaging and activating BAX
18.  
As synthetic PUMA BH3 peptides are predominantly unstructured in solution
32 (Figure 2-1), we 
first sought to stabilize the physiologically-relevant α-helical structure by insertion of an all-
hydrocarbon crosslink. By replacing i, i+4 pairs of native residues with non-natural amino acids 
bearing olefin tethers followed by ruthenium-catalyzed olefin metathesis, we previously 
generated a variety of stabilized alpha-helices of BCL-2 domains (SAHBs) modeled after the 
BH3 motifs of BCL-2 family proteins
33-35. In designing stapled peptides - whether for in vitro 
binding studies, cellular localization analyses, structure determination, cellular signal 
transduction studies, or in vivo activity analyses - synthetic iteration is required to achieve 
optimal solubility, structural stability, cell permeability, and biological activity for the desired 
application. In the case of our prototype BIM SAHBA
18
, which potently bound to and activated 
BAX, adjustments in both sequence and charge were required to enhance solubility and weaken 
binding potency in order to capture the transient “hit and run” interactions
15,17. In contrast, for  
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Figure 2-1 
 
Circular dichroism analysis of PUMA BH3.  A PUMA BH3 peptide composed of residues 
131-153 is relatively unstructured in solution, as reflected by the circular dichroism spectra and 
the percent α-helical content. 
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cellular work performed in the low micromolar range, the prototype BIM SAHBA (+2 charge) was 
optimal
15,36, given its enhanced target binding potency and capacity to penetrate intact cells.   
Thus, as for our development of BIM and MCL-1 SAHBs for a diversity of 
applications
15,18,34,36, we initiated our synthetic efforts here by generating a panel of PUMA 
SAHB constructs (designated PUMA SAHBs A1-A8) of differential sequence composition, 
length, and charge. In a screening fluorescence polarization binding assay against anti-
apoptotic BCL-XLΔC, we observed a binding affinity range of 2.6-13 nM for this panel of PUMA 
SAHBA1 peptides (Figure 2-2A). Guided by our learnings from BIM SAHBA, we selected a 
relatively low affinity compound bearing the most negative charge for in vitro biochemical and 
structural analyses, given our goal of evaluating functional interactions with BAX, in addition to 
the anti-apoptotic targets.  
For optimal comparison, we aimed to examine a PUMA SAHB bearing a staple in the 
same location used for our prior studies with BIM SAHBA. However, as for BIM SAHBs
15, we 
also wanted to confirm that any single staple location did not independently impact biochemical 
activity. Therefore, we also generated a panel of PUMA SAHBs A-L with differential localization 
of the hydrocarbon staple (Figure 2-2B). This “staple scanning” approach not only serves to 
dissociate any individual staple location from overall observed biochemical activity but also 
identifies the best binders and, importantly, those key residues and interfaces to avoid for staple 
placement, providing valuable structure-activity relationship information
15,34. In each case, 
PUMA SAHBs with hydrocarbon staple placements that avoid the core hydrophobic binding 
interface and conserved BH3 residues, exhibit nanomolar BCL-XLΔC binding affinity in the 4-21 
nM range. In contrast, staples that replace key hydrophobic or charged residues of the binding 
interface, as found in PUMA SAHBs C, E, I, and J, manifest relatively impaired binding activity. 
As would be predicted, positioning the staple directly at the binding interface while also 
replacing the universally conserved leucine residue, as in PUMA SAHBH, is most detrimental.   	 ﾠ 50	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Figure 2-2 
 
 
 
Sequence composition and anti-apoptotic binding activity of a panel of hydrocarbon-
stapled PUMA BH3 peptides.  (A) A series of FITC-PUMA SAHBA peptides of differential BH3 
domain length and (B) FITC-PUMA BH3 (131-153) constructs with varying staple positions (as 
reflected by the “staple walk” along the pictured helical wheel) were synthesized and screened 
for BCL-XLΔC binding activity by fluorescence polarization assay. 	 ﾠ 51	 ﾠ
Biophysical and anti-apoptotic binding characterizations of PUMA SAHBA1 and its negative 
control point mutant 
Based on the above analysis, we chose PUMA SAHBA1 to advance our in vitro studies of 
PUMAʼs pro-apoptotic activity due to the constructʼs (1) high affinity for known anti-apoptotic 
targets, (2) negative charge (which enhances solubility and optimized in vitro behavior for 
biochemical and structural studies), , and (3) similarity to a stapled BIM peptide previously used 
in BAX activation studies. Using this peptide as a starting reagent, we also generated a negative 
control construct for PUMA SAHBA1 by swapping the location of an alanine residue at position 
139 with the universally conserved leucine at position 141. Importantly, PUMA SAHBA1 and its 
A139L/L141A double point mutant, designated PUMA SAHBA1mut, exhibit similar, high 
percentage α-helical content, as assessed by circular dichroism (Figure 2-3A).   
When the corresponding FITC-derivatized analogs were subjected to anti-apoptotic 
protein binding analyses, PUMA SAHBA1 engaged BCL-2ΔC, BCL-XLΔC, BCL-wΔC, MCL-
1ΔNΔC, and BFL-1ΔC with dissociation constants in the 20-35 nM range, whereas 
A139L/L141A mutagenesis uniformly impaired binding activity, consistent with disruption of a 
major BH3 binding determinant (Figure 2-3B). Thus, we find that hydrocarbon stapling of the 
PUMA BH3 domain can potently enforce α-helical structure and the library of constructs obey 
predicted structure-activity relationships based upon BH3 sequence composition. Notably, 
PUMA SAHBA1 engages in high affinity, sequence-specific binding interactions with all anti-
apoptotic targets. 
 
PUMA SAHB directly binds to BAX by initial interaction at the α1/α6 trigger site 
To determine if a PUMA BH3 helix could likewise directly bind to the pro-apoptotic class 
of BCL-2 family proteins, as previously observed for BIM SAHB, we undertook an NMR analysis 	 ﾠ 52	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Figure 2-3  
 
 
Helicity and anti-apoptotic binding activity of PUMA SAHBA1 and its negative control 
point mutant.  (A) Circular dichroism of PUMA SAHBA1 and its A139L/L141A mutant 
demonstrated the marked α-helical structure of both stapled peptides in aqueous solution. *, 
exceeds the calculated ideal α-helicity of an undecapeptide standard
60. (B) FITC-PUMA SAHBA1 
(solid lines) exhibits high affinity binding to the diversity of anti-apoptotic BCL-2 family proteins, 
whereas A139L/L141A point mutagenesis (dashed lines) markedly impairs binding activity, 
highlighting the BH3 sequence-dependence of PUMA SAHBA1 engagement. Data are mean + 
S.D. for experiments performed in triplicate. X, stapling amino acid; B, norleucine. 	 ﾠ 53	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of 
15N-BAX upon PUMA SAHB titration.  Of note, the BAX-activating BIM BH3 interaction is 
transient, making the structural analysis of this dynamic process especially challenging
15. We 
thus employed PUMA SAHBA1, a relatively weaker binding PUMA SAHBA that also possessed 
the most negative charge (-2) to enhance solubility for high concentration NMR experiments, as 
described above.  We observed weak but dose-responsive backbone amide chemical shift 
changes in a discrete subset of BAX residues localized within α1, the α1-α2 loop, and α6, 
corresponding to the previously identified binding site for a stapled BIM BH3 helix
15 (Figure 2-
4). Upon increasing the PUMA SAHB:
15N-BAX ratio from 1:1 to 4:1 (Figure 2-4A, B), a series of 
chemical shift changes became more prominent in the α1-α2 loop (yellow), α2 (BH3) (teal), and 
α9 (pink), three regions previously implicated in BIM BH3-triggered N-terminal loop opening, 
BAX BH3 exposure, and C-terminal helix mobilization, respectively
17. These PUMA SAHB-
induced allosteric changes are consistent with induction of a major conformational change that 
is transmitted from the N-terminal face through the hydrophobic core to the C-terminal face, 
resulting in functional activation of BAX. 
To probe the PUMA SAHB interaction site on BAX by a second and completely distinct 
experimental approach, we developed and applied photoreactive PUMA SAHBs (pSAHBs). 
pSAHBs contain differentially localized benzophenone moieties, which covalently trap both 
static and dynamic protein interactors upon UV irradiation and enable the explicit localization of 
intercalation sites using mass spectrometry methods, as previously reported
37. To validate the 
binding specificity of PUMA pSAHBs-1 and -2, we first conducted crosslinking analysis with anti-
apoptotic BFL-1/A1ΔC, for which definitive structures are known. We found that the 
differentially-placed benzophenone moieties in each PUMA pSAHB crosslinked to discrete sub-
regions of the canonical BH3 binding pocket (Figure 2-5), precisely corresponding to the 
established structure of a PUMA BH3/BFL-1/A1ΔC complex
38 (PDB ID# 2VOF). Having  	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Figure 2-4 (next page) 
NMR analysis of 
15N-BAX upon PUMA SAHBA1 titration.  (A) At a 1:1 ratio of 
15N-PUMA 
SAHBA1/BAX, a series of chemical shift changes localize to surface residues of a1 and a6, 
corresponding to the previously defined trigger site (purple) for BIM BH3-induced direct BAX 
activation. Allosteric changes involving residues of the α1-α2 loop (yellow), α2 (teal), and α9 
(pink), as transmitted through the hydrophobic core (α4, α5), are also evident, and become 
more prominent upon titration up to a PUMA SAHBA1/BAX ratio of 4:1 (B). Ca atoms of BAX 
residues that undergo significant chemical shift change upon exposure to PUMA SAHBA1 are 
represented as orange bars on the plot (top) and orange spheres on the ribbon diagrams of 
monomeric BAX protein (calculated significance threshold >0.007 p.p.m. for 1:1 titration and 
>0.011 for 4:1 titration). 
 
	 ﾠ 
 	 ﾠ 55	 ﾠ
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 ﾠ
(
F
i
g
u
r
e
	 ﾠ
2
-ﾭ
4
,
	 ﾠ
c
o
n
t
.
)
	 ﾠ	 ﾠ 56	 ﾠ
Figure 2-5 
 
Photoreactive PUMA SAHBs localize the BH3 interaction site on BFL-1/A1ΔC with high 
fidelity.  PUMA pSAHBs-1 and -2 were incubated individually with anti-apoptotic BFL-1/A1ΔC 
and the mixtures subjected to UV irradiation, electrophoresis, excision of the crosslinked 
protein, trypsin proteolysis, and LC-MS/MS analysis. The plot (left) depicts the frequency of 
crosslinked sites identified across the BFL-1/A1ΔC polypeptide sequence for PUMA pSAHB-1 
(blue) and PUMA pSAHB-2 (red).  Mapping of PUMA pSAHB-crosslinked amino acids onto the 
BFL-1/A1ΔC structure (PDB ID# 2VOF) highlighted the capacity of PUMA pSAHBs to precisely 
localize the site of interaction at the canonical BH3-binding pocket. The frequency of 
crosslinking occurrence is reflected on the BFL-1/A1ΔC structure by the color scale for each 
PUMA pSAHB (1, blue; 2, red). 	 ﾠ 57	 ﾠ
validated the fidelity of PUMA pSAHBs-1 and -2, we subjected full-length BAX to the 
crosslinking analysis.  We found that PUMA pSAHB-1 almost exclusively crosslinked to BAX 
residues of the α1/α6 trigger site (Figure 2-6A), whereas PUMA pSAHB-2 reacted with residues 
at both the α1/α6 trigger site and α3 residues of the canonical BH3-binding pocket (Figure 2-
6B). BAX α9 effectively occludes the canonical BH3-binding pocket in the proteinʼs inactive 
state
39 and our NMR study only detects protein surface chemical shift changes involving the 
α1/α6 site upon ligand binding. Thus, the identified canonical pocket crosslinks are most likely 
indicative of a compatible secondary binding interaction that ensues upon allosteric release of 
α9 from the canonical pocket, which is induced by initial BH3 engagement of the α1/α6 trigger 
site.   
To explore this hypothesis, we repeated the PUMA pSAHB crosslinking studies on a 
mutant form of BAX in which the C-terminus was deleted (BAXΔC), thus exposing the canonical 
BH3-binding pocket from the outset. Strikingly, the balance of crosslinks completely shifted for 
both PUMA pSAHBs in favor of canonical pocket residues (Figure 2-7A, B). These data support 
a model in which exposure of the canonical BH3-binding pocket upon allosteric release of α9 
reveals a secondary PUMA BH3 interaction site that may be reflective of a sequential BH3-
mediated direct BAX activation mechanism. 
 
PUMA SAHB directly activates BAX-mediated pore formation 
To link the direct interaction between PUMA SAHB and BAX to its functional activation, 
we employed a reductionist liposomal system that measures BAX pore formation in a 
membrane environment upon the addition of discrete reagents. Whereas treatment with BAX, 
PUMA SAHBA1, or its A139L/L141A mutant alone had little to no effect on the liposomes, the 
combination of BAX and PUMA SAHBA1 yielded dose-responsive liposomal release of entrapped 
fluorophore (Figure 2-8A). Point mutagenesis of the PUMA BH3 interacting surface completely  	 ﾠ 58	 ﾠ
Figure 2-6 
 
BAX interaction site analysis by PUMA SAHB photoaffinity labeling and mass 
spectrometry.  (A) PUMA pSAHB-1 was incubated with full-length BAX and the mixture 
subjected to UV irradiation, streptavidin (SA) pulldown, electrophoresis, excision of the 
crosslinked protein, trypsin proteolysis, and LC-MS/MS analysis. A single arginine substitution 
(A150R) was made in PUMA pSAHB-1 to facilitate tryptic digestion into shorter and more 
identifiable fragments by MS. The plot (left) depicts the frequency of crosslinked sites identified 
across the BAX polypeptide sequence, with crosslinked residues mapped onto the solution 
structure of monomeric BAX (PDB ID 2K7W) (right) and colored according to the frequency of 
occurrence.  The C-terminal α9 helix of BAX has been removed from the structure to better 
visualize the crosslinked residues of the canonical BH3-binding pocket. The corresponding 
analysis was also performed for PUMA pSAHB-2 with full-length BAX (B).  	 ﾠ 59	 ﾠ
Figure 2-7 
 
Deletion of the C-terminal α9 helix of BAX increases PUMA SAHB photoaffinity labeling 
to the canonical BH3 binding pocket.  (A) PUMA pSAHB-1 was incubated with BAXΔC and 
the mixture subjected to UV irradiation, streptavidin (SA) pulldown, electrophoresis, excision of 
the crosslinked protein, trypsin proteolysis, and LC-MS/MS analysis. A single arginine 
substitution (A150R) was made in PUMA pSAHB-1 to facilitate tryptic digestion into shorter and 
more identifiable fragments by MS. The plot (left) depicts the frequency of crosslinked sites 
identified across the BAXΔC polypeptide sequence, with crosslinked residues mapped onto the 
solution structure of monomeric BAXΔC (PDB ID 2K7W) (right) and colored according to the 
frequency of occurrence. The corresponding analysis was also performed for PUMA pSAHB-2 
with BAXΔC (B). 	 ﾠ 60	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abrogated the effect (Figure 2-8B), underscoring the sequence-based specificity of PUMA 
SAHBA1 activity.  
Likewise, in the context of BAX/BAK-deficient mitochondria isolated from Alb-
cre
posBax
flox/-Bak
-/- mice, dose-responsive release of cytochrome c was only observed upon 
incubation with the combination of BAX and PUMA SAHBA1. Again, the specificity of PUMA 
SAHBA1 activity was confirmed by the inability of the mutant construct to activate BAX-mediated 
cytochrome c release. Whereas in the mitochondrial assay, the effect of PUMA SAHBA1 on BAX 
activity can be amplified by simultaneous inhibition of membrane-embedded anti-apoptotic 
proteins, the requirement of PUMA SAHBA1 to initiate BAX activation in both assays 
underscores the functional role of the direct PUMA SAHB/BAX binding interaction in triggering 
the membrane release activity of BAX. 
 
Generation of a cell permeable PUMA SAHB 
We next aimed to correlate our in vitro biochemical and structural findings to PUMA BH3 
activity in cells. Among the BH3-only proteins, PUMA has been implicated as a major driver of 
apoptosis induction in neurons and neuronal precursor cells
8,39-41. Therefore, we examined the 
pro-apoptotic activity of PUMA SAHBA1 in neuroblastoma cells, which can mount a substantial 
and clinically-relevant apoptotic blockade
42. We first screened PUMA SAHBA1 for cellular uptake 
by treating SH SY5Y neuroblastoma cells with the FITC-derivatized analog of PUMA SAHBA1 for 
six hours, followed by trypsinization, repeated washing, cellular lysis, electrophoresis, and 
fluorescence scan detection. A comparison of lysates from cells treated with the unmodified 
FITC-PUMA BH3 peptide and the corresponding A-stapled analog revealed no intracellular 
peptide fluorescence (Figure 2-9A), consistent with our prior observations that stapling of 
peptides alone does not uniformly confer cellular penetrance
43, particularly when the overall 
charge of the construct is less than zero
15,34,44, as is the case with PUMA SAHBA1.  	 ﾠ 61	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Figure 2-8 
 
PUMA SAHBA1 triggers BAX-mediated liposomal and cytochrome c release.  (A) PUMA 
SAHBA1 triggered dose-responsive BAX-mediated liposomal release of entrapped fluorophore 
(left), whereas BAX or PUMA SAHBs alone, or the combination of PUMA SAHBA1mut with BAX 
(right), had little to no effect. Data are mean + S.D. for experiments performed in triplicate and 
repeated twice. (B) BAX/BAK-deficient mitochondria dose-responsively released cytochrome c 
upon incubation with recombinant BAX and increasing amounts of PUMA SAHBA1, whereas 
BAX or PUMA SAHBs alone, or the combination of PUMA SAHBA1mut with BAX, had little to no 
effect. Data are mean + S.D. for experiments performed in sextuplicate and repeated three 
times. 
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Figure 2-9 
 
Characterization of cell permeable PUMA SAHBA2.  (A) SH SY5Y cells were treated with 
FITC-PUMA BH3 peptides (5 µM), followed by washing, trypsinization, cellular lysis, 
electrophoresis of the isolated supernatant, and fluorescence detection. Whereas little to no 
unmodified PUMA BH3 peptide or PUMA SAHBA1 fluorescence was detected in the 	 ﾠ 63	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(Figure 2-9, cont.) 
corresponding cellular lysates, PUMA SAHBA2 demonstrated robust fluorescence. (B) Circular 
dichroism demonstrated that, like PUMA SAHBA1 and its A139L/L141/A mutant, PUMA SAHBA2 
is predominantly α-helical in solution, with a calculated percent α-helicity of 74% based on the 
observed molar ellipticity at 222 nm. (C) Live cell confocal microscopy of SH SY5Y cells treated 
with FITC- PUMA SAHBA2 demonstrated its intracellular distribution. Prior to imaging, the cells 
were treated with Hoechst dye (blue) to label nuclei and CellMask Orange (orange-red) to 
delineate the plasma membrane. Original magnification, 100x. 	 ﾠ 64	 ﾠ
To facilitate cellular penetrance, we previously adjusted the overall charge of α-helical 
stapled peptides from <0 to the 0 to +2 range either by converting aspartic and glutamic acid 
residues to asparagines and glutamines
45, or by shifting the sequence composition to eliminate 
N- or C-terminal negatively charged residues and/or include N- or C-terminal positively charged 
residues
15,34,35. Thus, we eliminated the N-terminal glutamic acid of PUMA SAHBA1 and 
appended two native C-terminal arginines, converting the overall peptide charge from -1 to +2, 
while maintaining high α-helical content (Figure 2-9B) and analogous binding activity (see 
Figure 2-2A). When the FITC-derivatized analog of this alternate construct, PUMA SAHBA2, 
was subjected to cellular uptake analysis, a robust fluorescent band was detected in the lysate 
of treated cells (Figure 2-9A). Live cell confocal microscopy of FITC-PUMA SAHBA2-treated SH 
SY5Y cells further confirmed peptide uptake and its intracellular distribution (Figure 2-9C).  
 
PUMA SAHB induces caspase 3/7 activation and cell death by engagement of anti- and pro-
apoptotic targets 
With a cell permeable version of PUMA SAHB in hand, we treated a series of 
neuroblastoma cells, including SH SY5Y, Kelly, and IMR5, and measured cell viability at 24 
hours. In each case, a dose-responsive impairment in cell viability was observed (Figure 2-10, 
A-C, left), which correlated with dose-responsive caspase 3/7 activation, as measured at eight 
hours (Figure 2-10, A-C, right). To investigate whether the observed caspase 3/7 activation 
and cell death correlated with PUMA SAHB engagement of BCL-2 family targets, we incubated 
cellular lysates from each of the three cell lines with an N-terminal biotinylated analog of PUMA 
SAHBA, followed by streptavidin pull-down, and western analysis. In each case, a diverse 
spectrum of BCL-2 family targets was engaged, as reflected by PUMA SAHB pull-down of anti-
apoptotic BCL-2 and MCL-1, and pro-apoptotic BAX (Figure 2-11, A-C). Taken together, these 
data demonstrate that cell permeable PUMA SAHBA2 can activate the death pathway in  	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Figure 2-10 (next page) 
Cell permeable PUMA SAHBA2 engages a diversity of BCL-2 family targets, activates 
caspase 3/7, and decreases the viability of neuroblastoma cells.  (A-C) PUMA SAHBA2 
dose-responsively impaired the viability of a series of neuroblastoma cell lines including SH 
SY5Y, Kelly, and IMR5, as measured by CellTiter-Glo at 24 hours after treatment (left).  The 
observed decrease in cell viability corresponded to dose-responsive caspase 3/7 activation, as 
measured by Caspase-Glo at eight 8 hours after treatment (right). Data are mean + S.D. for 
experiments performed in triplicate. 
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(Figure 2-10, cont.) 
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Figure 2-11 
 
A biotinylated version of PUMA SAHB co-precipitates native anti- and pro-apoptotic BCL-
2 family proteins.  Incubation of cellular lystates with biotinylated PUMA SAHBA3, followed by 
streptavidin pull-down, washing, electrophoresis of eluates, and BCL-2 family western analysis, 
documented engagement of native MCL-1, BCL-2, and BAX in all three neuroblastoma lines (A-
C). 	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neuroblastoma cells, and this biological activity correlates with the capacity of a biotinylated 
PUMA BH3 helix to bind both anti- and pro-apoptotic BCL-2 family members. 
 
Specificity and physiologic relevance of PUMA SAHB activity 
An important measure of pro-apoptotic specificity for ligands designed to operate via the 
BCL-2 family pathway is whether death induction occurs in a BAX/BAK-dependent fashion. 
Thus, we treated wild-type and Bax
-/-Bak
-/- mouse embryonic fibroblasts (MEFs) with PUMA 
SAHBA2 and measured cell viability and caspase 3/7 activation, as performed for the 
neuroblastoma cell lines. Albeit at a higher dosing range, PUMA SAHBA2 dose-responsively 
impaired cell viability of wild-type MEFs, with caspase 3/7 activation observed at the 
corresponding doses that induced cell death (Figure 2-12A). In contrast, little to no effect of 
PUMA SAHBA2 was observed in Bax
-/-Bak
-/- MEFs, with cell viability maintained in the 80-100% 
range and no activation of caspase 3/7 (Figure 2-12B).  
Finally, we explored whether or not the protein interactions of stapled PUMA BH3 
helices, and their observed functional consequences, bear on the physiologic interactions of full-
length PUMA protein. Flag-PUMAα was transiently transfected into human embryonic kidney 
293T cells and immunoprecipitated using anti-Flag resin. As observed for biotinylated PUMA 
SAHBA3, Flag-PUMA engaged a diversity of anti- and pro-apoptotic BCL-2 family targets, as 
reflected by western analysis detection of BCL-2, MCL-1, and BAX (Figure 2-13). As for the 
PUMA SAHB pull down, the relative ratio of Flag-PUMA pull down to protein input was greater 
for anti-apoptotic BCL-2 and MCL-1 than pro-apoptotic BAX, reflecting either (1) the more stable 
nature of BH3/anti-apoptotic interactions compared to BH3/pro-apoptotic interactions or (2) a 
frank preference for PUMA BH3 engagement of anti-apoptotic targets and once this reservoir is 
saturated, direct activation of pro-apoptotic targets can ensue.  
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Figure 2-12 
 
PUMA SAHBA2 activity is BAX/BAK-dependent.  (A-B) PUMA SAHBA2 dose-responsively 
impaired the viability of wild-type mouse embryonic fibroblasts (MEFs), but had little to no effect 
on Bax
-/-Bak
-/- MEFs, as measured by CellTiter-Glo at 24 hours after treatment (left column). 
Correspondingly, dose-responsive caspase 3/7 was observed in wild-type MEFs but not in Bax
-/-
Bak
-/- MEFs, as measured by Caspase-Glo at 8 hours after treatment (right column). Data are 
mean + S.D. for experiments performed in triplicate and repeated four times. 
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Figure 2-13 
 
Full-length PUMA protein, expressed in HEK 293T cells, targets native anti- and pro-
apoptotic BCL-2 family proteins.  Flag-Puma α or vector control was transiently transfected 
into human embryonic kidney 293T (HEK 293T) cells and lysates subjected to 
immunoprecipitation using Flag affinity beads, followed by washing, and electrophoresis of 
eluates. Western analysis of MCL-1, BCL-2, BAX, PUMA, and GAPDH confirmed PUMA 
pulldown of both anti- and pro-apoptotic proteins. 	 ﾠ 71	 ﾠ
Taken together, these data demonstrate that PUMA BH3 harbors the biochemical 
capacity to engage both anti- and pro-apoptotic BCL-2 family proteins and, depending on the 
cellular context, may harness this multimodal interaction potential to activate the apoptotic 
pathway.   
 
Discussion 
PUMA is a potent pro-apoptotic BH3-only protein implicated in a variety of apoptotic 
signaling pathways and subject to transcriptional and post-translational regulation
6. Like BIM, 
PUMA broadly interacts with BCL-2 family anti-apoptotic proteins, and the two proteins have 
been shown to compensate for and cooperate with one another in a variety of physiologic death 
pathways
42,45-47. Published biochemical, cellular, and in vivo studies differ, however, on whether 
a component of PUMAʼs pro-apoptotic potency also derives from its capacity to directly engage 
pro-apoptotic proteins, as demonstrated for BID and BIM. Notably, alignment of BCL-2 family 
BH3 domains reveals that PUMA BH3 is most similar to the BH3 domains of BIM and BAX in 
that very region implicated in direct interaction at the recently identified α1/α6 trigger site of 
BAX
15,17, with a highly homologous hydrophobic and electrostatic distribution reflected by the 
consensus LRR(I/M)(A/G)D(D/E) (Figure 2-14). Thus, based on the defined BIM BH3 triggering 
and BAX BH3 auto-propagating interactions at the α1/α6 site, it seemed likely that PUMA BH3 
could likewise bind BAX at this same location.  
Indeed, by two separate methods, NMR and mass spectrometry analysis of PUMA 
pSAHB-labeled BAX, we identified PUMA BH3 interaction at the α1/α6 interface. We linked this 
binding event to direct and functional activation of BAX in both liposomal and mitochondrial 
assay systems, in which PUMA SAHB dose-responsively triggered BAX-mediated release 
activity in a BH3 sequence-dependent manner. The physiologic relevance of these structural 
and biochemical findings are supported by the capacity of PUMA SAHB and PUMA protein to  	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Figure 2-14 
 
Sequence homology of BIM, BAX, and PUMA BH3 domains.  Alignment of the human BH3 
domains of BIM, BAX, and PUMA demonstrates the high degree of sequence homology in the 
core BH3 region that engages in complementary hydrophobic and electrostatic interactions at 
the BAX α1/α6 trigger site. Hydrophobic, acidic, and basic residues of the consensus sequence 
are shown in yellow, red, and blue, respectively. 	 ﾠ 73	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likewise engage native anti-apoptotic BCL-2 family proteins and BAX in cells. Taken together, 
these data support a model in which PUMA can function as a direct activator of BAX, consistent 
with a recent study documenting that in the absence of the direct activators BID, BIM, and p53, 
PUMA was sufficient to activate BAX
45.  
     In mapping the PUMA BH3 interaction site by pSAHB-based photoaffinity labeling, the 
majority of crosslinked residues in full-length BAX localized to the α1/α6 trigger site, yet a small 
subset included residues of the canonical BH3-binding pocket. As the chemical shift changes 
observed by NMR upon PUMA SAHBA1 binding primarily involved surface residues of the α1/α6 
trigger site, we suggest that allosteric release of α9 upon triggering at the N-terminal site 
exposes the canonical pocket, which is likewise compatible with PUMA BH3 binding. Indeed, 
when we performed the site identification analyses with C-terminally deleted BAX, the PUMA 
pSAHB crosslinking pattern shifted to predominantly involve residues of the canonical pocket. A 
similar compatibility for activator BH3 domains at the traditional BH3-binding pocket was also 
observed for C-terminally deleted BAK
14, which naturally resides in the mitochondrial 
membrane. These data suggest that activator BH3-engagement at the canonical pocket may 
represent a common mechanism for maintaining mitochondrial-localized BAK and BAX in an 
activation-competent state, with the α1/α6 triggering mechanism of BAX representing a unique 
afferent step required to regulate the activation and mitochondrial translocation of cytosolic BAX.  
The stability and high affinity of BH3-only interactions with anti-apoptotic BCL-2 family 
proteins suggests that upon BH3-only deployment in response to cellular stress, the principal 
wrestling site between pro-life and pro-death forces may reside in these neutralizing complexes. 
However, with continued pro-apoptotic signaling, displacement of activator BH3-only proteins 
from anti-apoptotics or depletion of the anti-apoptotic reservoir, produces a BID/BIM/PUMA 
overflow that directly activates BAX and BAK at their respective BH3 trigger sites (Figure 2-15). 
Importantly, the very potency of PUMA and the capacity of its BH3 helix to engage native anti-  	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Figure 2-15 
 
A model for multimodal activation of BCL-2 family proteins by PUMA. Cellular stresses 
activate BH3-only proteins, including both direct and indirect activators. Both sets of proteins 
bind to and deplete the anti-apoptotic protein reservoir, thereby lowering the apoptotic threshold. 
As long as the burden of anti-apoptotic proteins outweighs that of the pro-apoptotics, cellular 
viability is maintained. If persistent stress is incurred, additional BH3-only proteins are activated. 
The anti-apoptotic reservoirs become fully neutralized, and direct activators BID, BIM, and 
PUMA bind and directly activate pro-apoptotic BAX and BAK, inducing apoptosis. 	 ﾠ 75	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and pro-apoptotic BH3-binding pockets, suggests that pharmacologic mimicry of this 
functionality carries the potential to reactivate apoptosis in the context of resistant cancer, as 
observed here for neuroblastoma. Indeed, the BH3-binding pockets of both anti- and pro-
apoptotic BCL-2 family proteins are bona fide drug targets. Whereas therapeutic targeting of the 
anti-apoptotic BCL-2/BCL-XL canonical groove in the form of ABT-737, -263, and -199 has led 
the way for “inhibiting the inhibitors” of apoptosis
48, new approaches to “activating the activators” 
by simulating BIM and PUMA engagement of BH3 trigger sites on BAX/BAK are underway
36,49 
and may add a new dimension to the growing arsenal of BCL-2 family modulators.        
 
Methods 
Stapled peptide synthesis and characterization. SAHBs were synthesized, derivatized, 
purified to >95% homogeneity by LC/MS, quantified by amino acid analysis, and subjected to 
circular dichroism (Aviv Biomedical spectrophotometer) in 5 mM potassium phosphate buffer, 
pH 7.4, as previously described
43,50,51. X = (S)-N-Fmoc-2-(4ʼ-pentylenyl)alanine [S5]; U = 4-
benzoylphenylalanine, B = norleucine.  
 
Recombinant protein production.  BCL-2ΔC, BCL-XLΔC, BCL-wΔC, MCL-1ΔNΔC, BFL1ΔC, 
and BAX were produced and purified as described
15,36. Briefly, BCL-2ΔC, BCL-XLΔC, BCL-wΔC, 
and MCL-1ΔNΔC were expressed as glutathione-S-transferase (GST) fusion proteins in 
Escherichia coli BL21 (DE3) from the pGEX2T vector (Pharmacia Biotech) and purified by 
affinity chromatography using glutathione sepharose beads (GE Healthcare), followed by 
thrombin cleavage of the GST tag. GB1-BFL1ΔC-His was similarly expressed in Escherichia coli 
BL21 (DE3) from the pGEV2 vector, purified by affinity chromatography using nickel-NTA 
agarose beads (Qiagen), and eluted according to the manufacturerʼs instructions. BAX was 
expressed in Escherichia coli BL21 (DE3) from the pTYB1 vector and purified by affinity 	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chromatography using chitin beads (New England BioLabs), and the chitin tag cleaved by 
overnight incubation in 50 mM dithiothreitol. In each case, pure, monomeric protein was isolated 
by gel filtration FPLC. 
 
Fluorescence polarization binding assay.  FITC-PUMA SAHBs (50 nM) were added to serial 
dilutions of recombinant protein in binding buffer (100 mM NaCl, 50 mM Tris, pH 8.0) in 96-well 
black opaque plates. The plates were incubated in the dark at room temperature until 
equilibrium was reached, and then fluorescence polarization was measured by a microplate 
reader (Spectramax M5 Microplate Reader, Molecular Devices). Dissociation constants (KD) 
were calculated by nonlinear regression analysis of dose-response curves with Prism software 
5.0 (GraphPad).  
 
NMR analysis. Uniformly 
15N-labeled full-length human BAX was generated as previously 
described
15,52. Protein samples were prepared in 25 mM sodium acetate, 50 mM NaCl solution 
at pH 6.0 in 5% D2O. PUMA SAHBA1 (6 mM stock) was titrated into a solution of 50 mM BAX to 
achieve the indicated molar ratios. Correlation 
1H-
15N HSQC spectra
53 were acquired at 25°C on 
a Bruker 800 MHz NMR spectrometer equipped with a cryogenic probe, processed using 
NMRPipe
54, and analyzed with NMRView
55. The weighted average chemical shift difference Δ at 
the indicated molar ratio was calculated as [{(ΔH)
2 + (ΔN/5)
2}/2]
1/2 in p.p.m. The absence of a 
bar indicates no chemical shift difference, or the presence of a proline or residue that is 
overlapped or not assigned. BAX cross-peak assignments were applied as previously 
reported
52. The significance threshold for backbone amide chemical shift changes was 
calculated based on the average chemical shift across all residues plus the standard deviation, 
in accordance with standard methods
56. 
 	 ﾠ 77	 ﾠ
Binding site identification by pSAHB photoaffinity labeling and mass spectrometry. 
Recombinant protein (10 mM) and biotinylated pSAHB (30 mM) were mixed and then irradiated 
(365 nm, Spectroline Handheld UV Lamp Model En280L, Spectronics Corp.) for 1.5 hours on 
ice. Unreacted peptide was removed from the irradiated samples by overnight dialysis at 4°C in 
dialysis buffer (200 mM NaCl, 50 mM Tris, pH 7.5) using 6–8 kD molecular weight cutoff D-Tube 
dialyzers (EMD Biosciences). Biotinylated species were captured by incubation with high-
capacity streptavidin agarose (Thermo) for 2 hours at 4°C. Streptavidin beads were sequentially 
washed at room temperature three times each in 1% SDS in PBS, 1 M NaCl in PBS, and 10% 
ethanol in PBS, boiled 2 x 10 minutes in a 10% SDS solution (Promega) containing D-biotin (10 
mg/ml), the eluates electrophoresed using 4%-12% gradient Bis-Tris gels (Invitrogen), and then 
stained for protein content by Coomassie Blue. The crosslinked bands were excised and 
prepared for mass spectrometry analysis as previously described
37. Samples were subjected to 
LC-MS/MS in an LTQ Orbitrap XL hybrid mass spectrometer (ThermoFisher, San Jose, CA). 
MS/MS spectra were searched using the SEQUEST algorithm
57 against a partially tryptic 
database of the relevant protein. Benzophenone-crosslinked tryptic fragments were identified by 
using the mass of the tryptic fragment of the pSAHB peptide as a required modification. 
Reversed protein sequences were used to generate an estimate of the false discovery rate. 
Identified crosslinked peptides were filtered based on tryptic state, charge state, mass accuracy, 
and number of crosslinks per peptide. 
 
Liposomal release assay. Liposomes were generated and applied in BAX-mediated release 
assays as described
17,58.  Briefly, a lipid mixture composed of a 48:28:10:10:4 molar ratio of 
phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, dioleoyl 
phosphatidylserine, and tetraoleolyl cardiolipin (Avanti Polar Lipids) in chloroform was generated 
to mimic the lipid composition of the outer mitochondrial membrane. Solvent was removed by 	 ﾠ 78	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evaporation under nitrogen gas and then by vacuum for two hours. Lipid films were hydrated in 
liposome buffer (150 mM KCl, 20 mM HEPES, pH 7.0) and mixed with 12.5 mM ANTS 
fluorophore and 45 mM DPX quencher. After five freeze-thaw cycles, the mixture was extruded 
through 100 nm nucleopore polycarbonate membranes (Avestin) and intact liposomes purified 
by gel filtration chromatography using a 10 mL Sepharose CL2B column (GE Healtcare). To 
monitor ligand-triggered BAX-mediated release, liposomes were incubated in liposome buffer 
with the indicated amounts of recombinant monomeric BAX and PUMA SAHBs in black opaque 
96 well plates (total reaction volume, 100 mL).  ANTS/DPX release was monitored over a 120 
minute period in a spectrofluorometer (Tecan Infinite M1000) using an excitation wavelength of 
355 nm, an emission wavelength of 540 nm, and a bandwidth of 20 nm. Maximal release was 
determined by addition of Triton X-100 to a final concentration of 0.2% (v/v).  Percent release 
was calculated as [(F-F0)/(FTriton-F0)] x100, where F is the observed release, and F0 and F100 are 
baseline and maximal fluorescence, respectively. 
 
Cytochrome c release assay.  Mouse liver mitochondria (1.0 mg/mL) were isolated from Alb-
cre
posBax
fl/-Bak
−/− mice as described
33, and incubated with the indicated combinations of 
recombinant BAX and PUMA SAHBs at 37°C for 40 minutes. The pellet and supernatant 
fractions were isolated by centrifugation, and released cytochrome c was quantitated using a 
colorimetric ELISA assay (R&D Systems). Percent cytochrome c released into the supernatant 
(%cytocsup) from releasable mitochondrial pools was calculated according to the following 
equation: %cytoc=[(cytocsup-cytocbackgr)/(cytoctotal-cytocbackgr)]x100, where background release 
represents cytochrome c detected in the supernatant of vehicle-treated 
samples and total release represents cytochrome c measured in 1% Triton X-100-treated 
samples.  
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Cell culture. Wild-type (WT) and Bax
-/-Bak
-/- (DKO) mouse embryonic fibroblasts (MEFs) and 
human embryonic kidney (HEK) 293T cells were maintained in DMEM (Invitrogen) 
supplemented with 10% FBS, 100 U/mL penicillin/streptomycin, 2 mM L-glutamine, 0.1 mM 
nonessential amino acids, and 50 mM b-mercaptoethanol. Neuroblastoma cell lines SH SY5Y, 
Kelly, and IMR5 were maintained in RPMI 1640 GlutaMAX (Invitrogen) supplemented with 10% 
FBS and 100 U/mL penicillin/streptomycin.  
 
Cellular uptake analysis.  SH SY5Y cells were plated in 6-well plates at 5x10
5 cells per well 
and, after overnight incubation, full media was removed and replaced with OptiMEM (Invitrogen) 
containing 100 U/mL penicillin/streptomycin. FITC-PUMA peptide (1 mM stock in DMSO) or 
vehicle was diluted into 1 mL cultures for a final treatment concentration of 5 mM and incubated 
at 37°C for 6 hours, followed by washing twice in PBS, trypsinizing for 10 minutes to remove any 
surface-bound peptide, and washing in PBS twice more. Cells were then lysed in 1% CHAPS 
buffer on ice and incubated for 20 minutes. Supernatants were collected after table top 
centrifugation, electrophoresed, and intracellular FITC peptide detected by fluorescence imaging 
using a Typhoon 9400 (GE Healthcare Life Sciences). For live cell confocal microscopy, SH 
SY5Y cells were plated in poly-D-lysine-coated culture plates (MatTek Corporation) at 2x10
5 
cells per well and, after overnight incubation, full media was replaced with OptiMEM (Invitrogen) 
containing 100 U/mL penicillin/streptomycin. FITC-PUMA peptide (1 mM stock in DMSO) or 
vehicle was diluted into 1 mL cultures for a final treatment concentration of 10 mM and 
incubated at 37°C. After 6 hours, cells were incubated with CellMask Orange (5 µg/mL) and 
Hoeschst 33342 (5 µg/mL, Invitrogen) for 10 minutes, followed by washing three times with PBS 
and incubation with DMEM media lacking phenol red. Confocal images were acquired on a 
Yokogawa CSU-X1 spinning disk confocal system (Andor Technology) attached to a Nikon Ti-E 	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inverted microscope (Nikon Instruments). Excitation of the three fluorophores was performed 
sequentially using 405 nm, 488 nm, and 561 nm lasers. Images were acquired using a 100x 
Plan Apo objective lens with a Hamamatsu OrcaER camera (Hamamatsu Photonics). 
Acquisition parameters, shutters, filter positions, and focus were controlled by Andor iQ software 
(Andor Technology). 
 
Cell viability and caspase-3/7 activation assays.  Cells were plated in 96-well plates at 
2.5x10
3 cells per well and, after overnight incubation, full media was replaced with OptiMEM 
containing 100 U/mL penicillin/streptomycin. A serial dilution of PUMA SAHBA2 from a 1 mM 
DMSO stock or vehicle was added to the cells in a final volume of 100 mL and incubated at 
37°C for 6 hours, followed by addition of 10 mL FBS. To measure caspase-3/7 activation, cells 
were analyzed after eight hours of total treatment using the Caspase-Glo 3/7 
chemiluminescence reagent (Promega). For cell viability analysis, cells were analyzed after 24 
hours of total treatment using the CellTiter-Glo chemiluminescence reagent (Promega). 
Luminescence was detected by a microplate reader (Spectramax M5 Microplate Reader, 
Molecular Devices).  
 
PUMA SAHB co-precipitation from cellular lysates. Neuroblastoma cells were trypsinized, 
collected by centrifugation, washed twice in cold PBS, and lysed in a 1% CHAPS buffer (50 mM 
Tris [pH 7.5], 200 mM NaCl, 1% [w/v] CHAPS, 1mM EDTA, 1.5 mM MgCl2, complete protease 
inhibitor tablet [Roche]), on ice for 20 minutes. Lysates were isolated after table top 
centrifugation and then incubated (1.25 mg) with 50 nmol biotinylated-PUMA SAHBA3 in lysis 
buffer overnight at 4°C. Biotin pull down was accomplished by incubation with high-capacity 
streptavidin agarose (Thermo) for 2 hours at 4°C, followed by washing the beads with 3 x 500 
mL lysis buffer. Precipitated proteins were eluted by treating the beads with 4x LDS buffer 	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containing 50 mM DTT for 10 minutes at 70°C, and then subjected to electrophoresis (25 mg 
protein/lane) and western blotting using the following antibodies: BAX N-20 (1:2000) (sc-493, 
Santa Cruz Biotechnology), BCL-2 (1:200) (sc-509, Santa Cruz Biotechnology), MCL-1 s-19 
(1:200) (sc-819, Santa Cruz Biotechnology).  
 
Cell transfection and Flag-PUMA co-immunoprecipitation.  HEK 293T cells were transiently 
transfected with pcDNA3 plasmid containing Flag-PUMAa using polyethylenimine
59 (PEI) at a 
4:1 PEI:DNA ratio. Two days following transfection, cells were lysed in 1% CHAPS buffer (as 
above) and isolated lysate (2 mg) was incubated with 30 mL of anti-Flag magnetic affinity beads 
(Sigma) in lysis buffer overnight at 4°C. The beads were washed with 3 x 500 mL lysis buffer, 
and immunoprecipitated proteins eluted by incubation with 4x LDS containing 50 mM DTT for 10 
minutes at 70°C. The immunoprecipitates were subjected to electrophoresis and analyzed by 
western blot using the above-described BAX, BCL-2, and MCL-1 antibodies.  
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Table 2-1: PUMA BH3 peptides.  
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Abstract 
  The protein OLIG2 plays a fundamental role in central nervous system development, 
regulating the differentiation of progenitor cells into neuronal subtypes and oligodendrocytes. 
Early in development, OLIG2 preserves these cells in a replication-competent state. OLIG2 also 
plays a similar role in tumor “stem cells,” serving to perpetually repopulate human gliomas. As a 
basic helix-loop-helix (bHLH) transcription factor, OLIG2 dimerizes through the interaction of two 
α-helices to carry out its downstream functions. We generated a series of stabilized alpha-
helices (SAHs) mimicking helical segments of the OLIG2 bHLH domain in an effort to inhibit 
dimer formation and potentially OLIG2 function. While hydrocarbon stapling successfully 
produced a number of α-helical peptides corresponding to the endogenous domain, none of the 
SAH-OLIG2 peptides specifically and potently disrupted OLIG2 dimerization or its subsequent 
binding to DNA, as assessed by EMSA assay. As an alternative approach to direct OLIG2 
targeting, we undertook a whole human genome yeast two-hybrid study of full-length OLIG2 to 
identify novel OLIG2 interaction partners. Several intriguing candidates, including the Wnt 
effector protein DVL3 and the regulator of embryonic neurogenesis LNX2, were identified and 
merit further study, both for their potential roles in OLIG2 biology and as alternate targets for 
indirect modulation of OLIG2. 
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Introduction 
  Transcription factors dictate the expression and stoichiometry of cellular proteins, 
making them master regulators of cell and tissue physiology. It is therefore not surprising that 
such control points are frequently mutated and deregulated in disease
1, making transcription 
factors potentially ideal targets for therapeutic intervention. However, transcription factors have 
long frustrated pharmacologic efforts due to the difficulty of targeting their protein-protein and 
protein-DNA interaction surfaces. Recently, strides have been made in modulating both of these 
classes of transcription factor interactions. For example, polyamides
2 and zinc finger nucleases
3 
have been used to target specific DNA binding sequences, while small molecules
4,5 and short 
peptides
6-11 have been designed to disrupt specific transcription factor-based protein binding 
interfaces. 
  Basic helix-loop-helix (bHLH) proteins are a large and diverse class of transcription 
factors that regulate numerous processes during the cellular life span. The canonical bHLH 
domain consists of a basic stretch of amino acids that contact the DNA, typically at an E-box 
consensus site
12, followed by two α-helices joined with a variable loop region. Homologous α-
helices of two transcription factor molecules can dimerize in a parallel orientation, stabilizing the 
dimer on the DNA and enabling downstream transcription
12,13. Many bHLH transcription factors 
can pair with a variety of partners, thereby exerting precise control over a range of diverse 
targets. 
  The bHLH protein OLIG2 was discovered over a decade ago as a critical mediator of 
oligodendrocyte and somatic motor neuron differentiation
14-16. While the majority of OLIG2 
protein is downregulated following development, OLIG2 remains active in a subset of adult 
neural precursor cells and in mature myelinating oligodendrocytes
17,18. OLIG2 functionally 
regulates both p21
19 and p53
20,21, allowing it to control entry into the cell cycle and cellular 
proliferation.  	 ﾠ 91	 ﾠ
  In addition to its developmental functions, OLIG2 is also a pathogenic factor in brain 
tumorigenesis. OLIG2 is expressed in 100% of diffuse gliomas, irrespective of grade
22,23, where 
it marks a subset of stem cell-like populations
19,24 that are highly resistant to radiation and 
chemotherapy
25. Notably, OLIG2 is not merely present in these cells but is strictly required for 
the development of glioma in a mouse model
19. Therapeutic disruption of OLIG2 function could 
thus be highly advantageous in the treatment of refractory gliomas. 
  Nature has already provided a solution for disrupting bHLH function. The Id proteins, 
which have a helix-loop-helix domain but lack a basic region and thus cannot bind to DNA, 
serve as natural dominant negatives in the cell through the formation of nonfunctional 
heterodimers
26. Several approaches have been made to artificially reproduce this disruption 
through the generation of bHLH domain peptide mimetics. Short peptides designed against 
Helix 2 of the bHLH protein E47 were able to disrupt E47 homodimerzation in vitro at low 
micromolar doses
7, while peptides designed against Helix 1 or the leucine zipper domain of the 
MYC/MAX heterodimer have also shown some efficacy in cellular systems
6,8,11.  
To evaluate the ability of short peptides to disrupt OLIG2 dimerization and DNA binding 
(Figure 3-1), we generated peptides designed against Helix 1, Helix 2, and the bHLH domains 
of OLIG2. Notably, in the studies described above, challenges in three areas emerged: 
successful mimicry of the native α-helical binding interface (shown to confer enhanced binding 
efficacy
6); prolonged proteolytic stability in a cellular environment
8; and selection of the optimal 
region to create a specific dominant negative peptide. To address the first two questions, we 
made use of a hydrocarbon crosslinking technique in which i,i+4 residues of the peptide are 
replaced with non-natural amino acids bearing terminal olefins that are covalently crosslinked by 
ruthenium-catalyzed olefin metathesis
27,28. This “stapling” approach frequently restores the 
native α-helicity of the peptide, as well as increasing proteolytic stability and cell penetrance
29. 
Using this approach, stabilized alpha-helices (SAHs) of OLIG2 domains were synthesized for  	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Figure 3-1 
 
Schematic of bHLH dimerization disruption using stapled peptides.  Basic helix-loop-helix 
transcription factors dimerize through their bHLH domains and engage target DNA (bHLH 
heterodimer of E47 and NeuroD1
30 shown here as an example). Addition of a dominant negative 
stapled peptide could disrupt an OLIG2 dimer, preventing downstream transcription. 	 ﾠ 93	 ﾠ
biochemical analysis. To address the third area of difficulty, we generated panels of SAH-OLIG2 
peptides for each domain (Helix 1, Helix 2, or bHLH) in order to comprehensively test a variety 
of peptides lengths, compositions, and charges. These peptides were then evaluated for their 
capacity to disrupt OLIG2 dimerization and DNA binding, in an effort to identify novel research 
tools and prototype therapeutics for disrupting pathologic OLIG2 activity in vitro and in vivo.  
 
 
Results 
   
Design, synthesis, and biophysical characterization of SAH-OLIG2 peptides 
In order to investigate the ability of short peptides to inhibit OLIG2 transcription factor 
activity, we designed and synthesized a panel of compounds corresponding to the α-helical 
segments of the bHLH domain of OLIG2 (Figure 3-2A,B). In addition, based on preliminary 
evidence that E12 is a binding partner of OLIG2 (C. Stiles, personal communication), peptides 
based on the bHLH domain of E12 were also generated to compare the efficacy of E12 and 
OLIG2 peptides in disrupting OLIG2 interactions (Figure 3-2C). The designed constructs vary in 
their staple position, charge, and sequence coverage of the indicated helical domains.  
In order to reinforce the native α-helicity of the bHLH sequences, non-natural amino 
acids were inserted into the peptides one α-helical turn apart (i,i+4) and chemically crosslinked 
by ruthenium-catalyzed olefin metathesis, yielding stabilized α-helices of OLIG2 and E12 
peptides. Circular dichroism analysis demonstrated a range of α-helical stabilization from 
installation of the various staples, spanning 23%-100% α-helical induction (Figure 3-2, A-C). In 
comparison, native peptides of either Helix 1 or Helix 2 sequences of OLIG2 were unstructured 
in solution, as determined by circular dichroism (Figure 3-2D). Thus, this preliminary library of 
peptides provided a range of SAH-OLIG2 and -E12 α-helical peptides for further evaluation. 
 
 	 ﾠ 94	 ﾠ
Figure 3-2 (next page) 
A panel of SAH-OLIG2 and -E12 peptides with varying lengths and staple positions show 
a range of α-helical stabilization. Stapled SAH-OLIG2.1 (A) and 2.2 (B) peptides and SAH-
E12.1 and 2.2 peptides (C) demonstrate a wide range of α-structural stabilization spanning 23-
100% α-helicity, as measured by circular dichroism analysis. In contrast, native, unstapled 
OLIG2 Helix 1 and Helix 2 peptides are relatively unstructured in solution (D). *, exceeds the 
calculated ideal α-helicity of an undecapeptide standard
31. X = S5 non-natural stapling amino 
acid, B = norleucine. 	 ﾠ 95	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(Figure 3-2, cont.) 
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Functional evaluation of SAH-OLIG2 peptides using electrophoretic mobility shift assays 
The SAH-OLIG2 peptides were screened for their ability to impact the formation of an 
OLIG2/DNA complex (and ultimately downstream transcriptional activity) by electrophoretic 
mobility shift assays (EMSAs). In these experiments, purified OLIG2 protein from COS-7 cells 
was pre-incubated with varying concentrations of SAH-OLIG2 and -E12 peptides, and the 
mixtures added to a 
32P-labelled double-stranded DNA probe containing an OLIG2 binding site. 
The proportion of DNA probe bound to OLIG2 was evaluated by polyacrylamide gel 
electrophoresis. Whereas peptides modeled after the Helix 1 portion of OLIG2ʼs bHLH domain 
(SAH-OLIG2.1A-I) or Helices 1 or 2 of E12 (SAH-E12.1A-C and SAH-E12.2A,B) showed no effect 
on complex formation, several peptides modeled after the OLIG2 bHLH Helix 2 (SAH-OLIG2.2A-
I) caused an unexpected increase, rather than decrease, in complex formation (Figure 3-3, A-
C).   
OLIG2 belongs to a family of highly homologous bHLH transcription factors, and it was 
therefore important to determine the specificity of the observed Helix 2 effects. Thus, peptides 
modeled after Helix 2 of the MYC and MAX bHLH leucine zipper proteins (SAH-MYC2A and 
SAH-MAX2A) were tested in the OLIG2 EMSA. While SAH-OLIG2.2D showed strong stabilization 
of the OLIG2/DNA complex, neither SAH-MYC2A nor SAH-MAX2A altered the dynamics of the 
complex (Figure 3-4A).  
  To rule out the possibility that hydrophobic or charge effects could account for the 
observed result, as opposed to sequence-specific binding, a scrambled version of SAH-
OLIG2.2C peptide was generated. This peptide, scr. SAH-OLIG2.2C, was synthesized such that 
the overall sequence composition and staple position remained constant but the location of the 
natural amino acids were randomly placed or scrambled. Surprisingly, this peptide exerted the 
same stabilization effect on the OLIG2/DNA complex, as evaluated by EMSA (Figure 3-4B), 
suggesting that amino acid composition or overall charge, rather than the linear sequence itself,  	 ﾠ 98	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Figure 3-3 (next page) 
Evaluation of SAH-OLIG2 and -E12 peptides by electrophoretic mobility shift assays 
(EMSA).  Purified OLIG2 from COS-7 cells was incubated with radiolabeled Hb9 E-box 
oligonucleotides in the presence or absence of increasing concentrations of SAH-OLIG2.1 (A), -
OLIG2.2 (B), and -E12 (C) peptides. Complexes and free DNA were separated by 
polyacrylamide gel electorphoresis. The top band represents protein-DNA complex, whereas the  
bottom band is free DNA probe. While neither SAH-OLIG2.1 nor SAH-E12 peptides showed any 
effect, several SAH-OLIG2.2 peptides appeared to increase the amount of shifted DNA 
complex. 
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Figure 3-4 
 
Specificity testing identifies charge, not sequence, as the driving force behind the 
observed SAH-OLIG2.2 activity. Purified OLIG2 from COS-7 cells was incubated with 
radiolabeled Hb9 E-box oligonucleotides in the presence or absence of increasing 
concentrations of SAH peptides for specificity analysis. (A) SAH-MYC and SAH-MAX Helix 2 
peptides were generated as bHLH family control peptides. While SAH-OLIG2.2A caused an 
increase in shifted DNA complex, neither SAH-MYC nor SAH-MAX had any effect. (B) A 
scrambled version of SAH-OLIG2.2C was generated, maintaining overall amino acid content, 
staple position, and charge but randomizing the linear sequence. Both SAH-OLIG2.2C and its 
scrambled control caused an increase in shifted DNA complex, suggesting that the observed 
effect was non-specific. 	 ﾠ 101	 ﾠ
was the driving force for the observed phenomenon. Additional testing of unrelated stapled 
peptides with positive charges (+4 and +7) identified charge as a major causal factor for the 
increased dimerization/DNA binding activity of OLIG2 (data not shown). Thus, the observed 
stabilization of the OLIG2/DNA complex was a charge-driven DNA binding effect, rather than a 
sequence-specific stabilization of the protein/DNA complex.  
 
Yeast two-hybrid binding assay for Olig2 subdomains 
  In an effort to determine the minimal binding determinants for OLIG2 dimerization, we 
decided to utilize a high throughput yeast two-hybrid approach to test the binding of OLIG2 
subdomains to one another (Figure 3-5A). Subdomains of OLIG2, as well as full-length OLIG2, 
the close homolog OLIG1, and the homeobox domain protein NKX2.2, were cloned into yeast 
two-hybrid vectors containing either activating or DNA-binding domains. (Figure 3-5B). Each 
construct was evaluated against all others for their ability to grow on selective media, resulting in 
a 10x10 matrix of binding partner pairings. Indeed, full-length OLIG2 homodimerized with itself, 
and heterodimerized with full-length OLIG1. Additionally, binding occurred between full-length 
OLIG2 and an OLIG2ΔN construct but not a OLIG2ΔC construct, suggesting an important role 
for the C-terminus of OLIG2 for dimerization. However, no constructs consisting of only the 
bHLH domain or its subcomponents were found to dimerize with OLIG2 (Figure 3-5C). These 
data indicated that (1) truncated regions of OLIG2 express poorly in yeast, as has been 
observed in human cells, (2) short peptide subcomponents of the OLIG2 bHLH domain are 
insufficient for engaging full-length OLIG2, or (3) the weighting of the applied yeast two-hybrid 
system toward low false positive rates (Type I errors) and high false negative rates (Type II 
errors) may have prevented observation of these (potentially lower affinity) complexes. 
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Figure 3-5 
 
Yeast two-hybrid analysis of full-length OLIG2 and its subdomains.  (A) Experimental 
outline of yeast two-hybrid analysis. A functional transcription factor is separated into activating 
domains (Ads) and DNA-binding domains (DBs), and the two domains are fused to two 
potentially interacting species. If the species do in fact interact, the activating and DNA-binding  	 ﾠ 103	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(Figure 3-5, cont.) 
domains are brought in close enough proximity to activate transcription, allowing for expression 
of a reporter gene. (B) Full-length human Olig2, Olig1, and Nkx2.2 cDNAs were cloned into 
yeast two-hybrid vectors containing ADs or DBs. Additionally, subdomains of Olig2 of 
decreasing size were generated and cloned into the same yeast two-hybrid vectors. (C) A 10x10 
matrix represents the yeast two-hybrid binding experiment of each transcription factor (full-
length or subdomain) paired with all others, using both orientations of ADs and DBs. Yellow 
cells represent expected interactions, while +s represent observed strength of interaction in the 
yeast two-hybrid system, as evidenced by colony formation on selective yeast extract peptone 
dextrose plates. While OLIG2 homodimerization and OLIG1-OLIG2 heterodimerization were 
observed, dimerization of full-length OLIG2 and its subdomains was not detected. 	 ﾠ 104	 ﾠ
Design, synthesis, and biophysical characterization of doubly-stapled SAH-OLIG2 peptides 
  Given the ambiguous results of the OLIG2 subdomain yeast two-hybrid interaction 
analysis, we decided to generate OLIG2 peptides that encompassed a larger portion of the 
bHLH dimerization domain in an effort to maximize potential sequence-specific interactions. To 
do so, peptides were synthesized that incorporated the C-terminal portion of the basic DNA-
binding region as well as the entirety of Helix 1, the loop, and Helix 2 of OLIG2. Since these 
peptides were designed to mimic two separate and defined helices, with helix-breaking prolines 
in the intervening loop region, hydrocarbon staples were inserted into both helical regions to 
induce α-helicity, creating double stabilized alpha-helical (dSAH) OLIG2 peptides. Additionally, 
the non-natural amino acids were placed two α-helical turns apart (i,i+7), rather than one (i,i+4), 
in order to stabilize a longer region of the peptide. A native sequence, unstapled peptide (OLIG2 
bHLH) and a scrambled version (scr. dSAH-OLIG2B) were also generated as negative control 
peptides. To evaluate the successful induction of α-helicity, circular dichroism was performed on 
both the OLIG2 bHLH and dSAH-OLIG2B peptides (Figure 3-6). Once again, while the 
unstapled peptide was unstructured, dSAH-OLIG2B was over 50% α-helical, confirming the 
efficacy of stapling in restoring α-helicity. 
 
Functional evaluation of dSAH-Olig2 peptides using electrophoretic mobility shift assays 
Next, the dSAH-OLIG2 peptides were screened for their ability to alter the formation of 
an OLIG2/DNA complex by EMSA, as described above. At μM dosages, addition of the dSAH-
OLIG2 peptides caused a decrease in observed OLIG2/DNA complex. However, addition of the 
dSAH-OLIG2 peptides to DNA alone resulted in a shifted species, suggesting that dSAH-OLIG2 
may be competing with OLIG2 for binding to the DNA target (Figure 3-7A). To address this 
question, a scr. dSAH-OLIG2B was incubated with DNA alone to evaluate nonspecific DNA 
binding. This control peptide also bound to the DNA probe at similar doses, suggesting a  	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Figure 3-6 
 
Double stapled, two helix SAH-OLIG2 peptides demonstrate enhanced α-helical 
character. Peptides corresponding to the C-terminal portion of the basic domain, Helix 1, the 
loop, and Helix 2 of OLIG2 were generated using i,i+7 staples. Stapling increased the α-helicity 
of the sequence by 2.5x fold, as demonstrated by circular dichroism analysis. X = S5 non-
natural stapling amino acid, Y = R8 non-natural stapling amino acid, B = norleucine. 
nonspecific disruption of the protein/DNA complex.  
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Figure 3-7 
 
dSAH-OLIG2 peptides compete non-specifically for DNA as assessed by EMSA.  (A) 
Purified OLIG2 from COS-7 cells was incubated with radiolabeled Hb9 E-box oligonucleotides in 
the presence or absence of increasing concentrations of dSAH-OLIG2A and -OLIG2B. 
Complexes and free DNA were separated by polyacrylamide gel electrophoresis. The top band 
represents protein-DNA complex, whereas the bottom band is free DNA probe. Both dSAH-
OLIG2A and -OLIG2B appeared to decrease the levels of protein-DNA complex at μM 
concentrations. However, incubation of scr. dSAH-OLIG2B with radiolabeled DNA alone showed 
an increase in shifted complex at equivalent concentrations (B), suggesting that the peptide was 
binding to and obstructing the DNA. 	 ﾠ 107	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nonspecific disruption of the protein/DNA complex (Figure 3-7B). These data suggest that 
neither short, singly-stapled helical peptides nor longer, doubly-stapled helical peptides of the 
OLIG2 bHLH domain could specifically bind and disrupt full-length OLIG2 dimerization and DNA 
binding. 
 
Generation of recombinant OLIG2 protein 
  Previous research on Olig2 has been carried out primarily using genetic and cellular 
systems, with little progress made on structural or biophysical characterization. This is in part 
due to the longstanding inability to generate OLIG2 in large quantities. To better accomplish our 
biochemical goals, we endeavored to develop a soluble construct of OLIG2 protein that could be 
expressed in a bacterial system. cDNA of human Olig2 was cloned into the pGEV2 vector
32, 
which fuses the B1 immunoglobulin binding domain of streptococcal protein G (GB1) followed 
by a short linker region to the N-terminus of the OLIG2 protein. Additionally, a hexahistidine tag 
was added to the C-terminus of the protein to facilitate protein purification by affinity 
chromatography (Figure 3-8A).  
  Purification of this construct using cobalt affinity resin and size exclusion 
chromatography yielded milligram quantities of soluble GB1-OLIG2 protein. The identity of the 
protein was confirmed by both Western blot and mass spectrometry analysis (Figure 3-8, B-D). 
The recombinant protein was then evaluated by EMSA for functionality. GB1-OLIG2 
successfully bound to the E-box of MycN, an OLIG2 transcriptional target, but not to the 
corresponding mutant E-box (Figure 3-8E), confirming the ability of the recombinant protein to 
bind to target-specific DNA.  
 
 
 	 ﾠ 108	 ﾠ
Figure 3-8 (next page) 
Production and purification of functional, recombinant GB1-OLIG2.  (A) Schematic of GB1-
OLIG2-His protein expressed from pGEV2 vector in E. coli bacteria. The GB1 tag increases 
solubility of the protein, while the His tag allows for efficient affinity-based purification. Prominent 
OLIG2 features include the triple phosphoserine motif and the bHLH dimerization domain.  (B) 
Size exclusion chromatography (SEC) of cobalt agarose-purified GB1-OLIG2-His protein shows 
two peaks, corresponding to the GB1-OLIG2-His monomer and dimer species. (C) Coomassie 
staining and Western blot analysis of collected SEC peaks confirmed the relative purity and 
identity of OLIG2. (D) Mass spectrometry analysis further confirmed the identity of the isolated 
protein as OLIG2. Tryptic sites are indicated by arrowheads, and identified peptide fragments of 
OLIG2 are highlighted in yellow. (E) GB1-OLIG2-His functionally recapitulates known OLIG2 
function, as shown by DNA binding in the EMSA using MycN oligonucleotide probes (left). The 
upper band represents DNA bound to GB1-OLIG2-His protein, whereas the lower band is free 
DNA probe. GB1-OLIG2-His binding was documented to be sequence-specific, as protein 
incubation with a mutant MycN E-box sequence caused no DNA shift (right). 	 ﾠ 109	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(Figure 3-8,cont.) 
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Improved EMSA assay allows for separation of DNA/peptide binding from potential 
protein/peptide disruption effect 
Our previous EMSA experiments determined that many of our charged peptides bound 
to DNA at high concentrations, resulting in an apparent shift of the radioactive DNA. While we 
have confirmed that this DNA binding was nonspecific, we were concerned that such an effect 
could have obscured specific binding of our SAH-OLIG2 and -E12 peptides to OLIG2. In an 
effort to quench this effect, non-specific DNA (dCdG oligonucleotides) was added to the 
experimental design. In this assay, examination of control bands identified a non-specific DNA 
binding band (top) and a specific protein-DNA complex band (middle). Upon addition of excess 
dCdG oligonucleotides, the non-specific DNA binding largely disappeared, allowing for 
evaluation of specific disruption of the protein-DNA complex.  
In addition to the difficulties of nonspecific DNA-peptide binding, we were also concerned 
about the variability of the expressed OLIG2 protein in mammalian cells. Previous experiments 
were performed with purified OLIG2 protein from COS-7 cells, with only 1-2 μg of purified 
protein obtained per preparation. Consequently, several independent purifications were required 
for the analysis of our full panel of stapled peptides. Thus, variability in purity and quantitation 
was unavoidable, potentially influencing the reproducibility of the EMSA results. Following 
successful purification of recombinant GB1-OLIG2 protein, we could apply a single purification 
batch for > 300 EMSA experiments, ensuring continuity of protein quality and quantity for the 
comparative experiments.   
Finally, while the binding of OLIG2 to the E-box of the Hb9 gene has been observed in 
p19 carcinoma cells
33, it has not been detected in neural progenitor cells (the more appropriate 
context for OLIG2). Work in the Stiles lab (Dana-Farber Cancer Institute) has identified a 
number of additional OLIG2 binding targets, including the E-box of the MycN gene (D. Meijer, 	 ﾠ 111	 ﾠ
personal communication). As such, we began to use MycN E-box oligonucleotides in our EMSA 
system as a higher fidelity OLIG2 binding target. 
With these improvements to our EMSA experimental set-up, all SAH-OLIG2, SAH-E12, 
and dSAH-OLIG2 peptides were retested for a specific OLIG2-DNA disruption effect (Figure 3-
9, A-E). However, none of the peptides showed a significant disruption of the OLIG2-DNA 
complex at 0.15 or 1.5 micromolar peptide dosing . We have thus determined that our singly- 
and doubly-stapled SAH-OLIG2 and E12 peptides have, to date, not proven to be a viable, 
sequence-specific approach for targeted disruption of OLIG2 dimerization and DNA binding. 
 
Discovery of putative novel interactors of OLIG2 using a whole genome yeast two-hybrid screen 
Given the inherent difficulty of directly targeting transcription factors, we also decided to 
investigate other potential mechanisms for therapeutic intervention by searching for novel 
OLIG2 interaction partners. We previously generated yeast two-hybrid constructs of full-length 
OLIG2 and its subdomains, as well as full-length NKX2.2, with both DNA-binding and activating 
domain fusions (Figure 3-10A). These 9 constructs were screened in a pooled format against a 
library of yeast two-hybrid constructs of the human genome. Initial hits were then confirmed with 
one-on-one match-ups, generating a list of putative OLIG2 interacting proteins (Figure 3-10B). 
The list included a number of intriguing hits.  
•  LNX2 (Ligand of Numb 2) is a scaffolding protein that can oligomerize through its 
PDZ and RING domains, functionalities that regulate subcellular localization of 
unrelated proteins. In particular, LNX2 controls the subcelluar localization of NUMB, 
a membrane-associated protein that modulates neurogenesis by regulating 
asymmetric cell division
34. 
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Figure 3-9 (next page) 
Evaluation of SAH-OLIG2, -E12, and dSAH-OLIG2 peptides by a refined EMSA.  Purified 
GB1-OLIG2 cells was incubated with radiolabeled MycN E-box oligonucleotides and excess 
dCdG oligonucleotides in the presence or absence of increasing concentrations of SAH-
OLIG2.1 (A), -OLIG2.2 (B), -E12 (C), dSAH-OLIG2 (D), and control SAH (E) peptides. 
Complexes and free DNA were separated by polyacrylamide gel electorphoresis. The top band 
represents protein-DNA complex, whereas the bottom band is free DNA probe. However, none 
of the peptides exhibited an effect at either 0.15 or 1.5μM doses. 	 ﾠ 113	 ﾠ
(Figure 3-9, cont.) 
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(Figure 3-9, cont.) 
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Figure 3-10 
  
Whole human genome yeast two-hybrid analysis of full-length OLIG2 and its subdomains 
identifies novel candidate OLIG2 interaction partners.  (A) Full-length human Olig2, Nkx2.2 
cDNAs were cloned into yeast two-hybrid vectors containing ADs or DBs. Additionally, 
subdomains of Olig2 of decreasing size were generated and cloned into the same yeast two-
hybrid vectors. (B) Following pooled screening of all AD and DB Olig2 vectors, one-on-one 
confirmations of all first-round hits yielded a list of putative OLIG2 interaction partners. For 
comparison, full-length homebox domain transcription factor NKX2.2 was also assayed in the 
yeast two-hybrid screen. 
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•  DEC1 (BHLHE40) is another member of the bHLH class of transcription factors and 
is thought to serve as a transcriptional repressor. Its known functions range from 
regulating circadian rhythm
35 to promoting cartilage differentiation
36. 
•  DVL3 (Dishevelled 3) is an integral member of the Wnt signaling cascade, 
transmitting an activation signal from the Frizzled membrane receptor to the 
nucleus
37. The interaction between DVL3 and Frizzled is mediated by DVL3ʼs PDZ 
domain: notably, the same domain that regulates oligomerization of the LNX2 
proteins.  
Future work will continue the validation of these interactions in mammalian cells, including an 
assessment of the structural and functional significance of the putative interactions. Through this  
work, we have identified a novel set of proteins that may serve as targets for indirect modulation 
of OLIG2 and its tumorigenic activity.   
 
Discussion 
  The bHLH transcription factor OLIG2 is a critical regulator of oligodendrocyte and 
somatic motor neuron development. With both antineural and proneural functions, OLIG2 can 
drive cells towards replication
33 or differentiation
38, depending on the cell type and stage of 
development. Aside from its developmental roles, OLIG2 is required for the formation of gliomas 
in both a mouse model
19 and from human brain tumor cells
20. Thus, there is significant interest 
in therapeutic targeting of OLIG2. As a bHLH transcription factor, OLIG2 must dimerize to stably 
bind DNA promoter and enhancer elements, recruit necessary co-factors, and exert its 
transcriptional effects. This dimerization is driven by parallel intertwining of two adjacent α-
helices. We endeavored to disrupt OLIG2 dimerization, and thereby inhibit its activity, through 	 ﾠ 117	 ﾠ
the generation of stabilized α-helical peptides that mimic subcomponents of the OLIG2 
dimerization domain.  
  A comprehensive panel of stabilized peptides modeled after Helix 1, Helix 2, and the 
entirety of the bHLH domain of OLIG2 was synthesized. Circular dichroism studies revealed a 
wide range of α-helical stabilization, confirming that in many cases, all-hydrocarbon stapling 
successfully restored the native conformation of the peptide sequence. Electrophoretic mobility 
shift assays were conducted with purified OLIG2 protein, either immunopurified from COS-7 
cells or generated recombinantly in E.coli, in order to evaluate the ability of the SAH constructs 
to disrupt OLIG2 dimerization and DNA binding. Unfortunately, none of the singly- or doubly-
stapled peptides significantly impaired the formation of an OLIG2/DNA complex. At this stage, 
without additional structural information about the OLIG2 homodimer (for which the newly 
produced recombinant OLIG2 protein should be helpful) or alternate strategies for potentially 
increasing targeting and binding affinity, short stabilized α-helical peptides have not proven to 
be a viable strategy for disrupting the dimerization of OLIG2 or its downstream oncogenic 
activities. 
  Previously, several groups have generated peptides consisting of Helix 1, Helix 2, or the 
leucine zipper of the bHLH-LZ proteins MYC and MAX to hinder formation of the pathologic 
dimer
6,8. Such attempts have had limited success at dimer disruption in vitro, with even less 
success in vivo. While some of the challenge may reflect proteolytic instability and lack of cell 
penetrance (issues at least partially remedied by hydrocarbon stapling
29), the necessity for high 
affinity, high specificity binding to a relatively featureless surface may ultimately represent the 
major obstacle. Indeed, thus far, stapled peptides have demonstrated therapeutic success when 
the targeted protein interaction is comprised of a helix-in-groove interface, allowing for 
numerous energetically favorable interactions between the stapled peptide helix and the protein 
target
10,29,39. Future attempts to engage the more featureless interaction surfaces of transcription 	 ﾠ 118	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factors may require additional chemical interventions to increase affinity. Alternatively, efforts to 
identify the “hot spots” for transcription factor engagement may provide a clearer roadmap for 
peptide design. 
  As an alternative approach to direct targeting of the OLIG2 dimerization domain, it may 
be feasible to intervene indirectly through targeting OLIG2 interaction partners – kinases, 
transcriptional co-regulator proteins, and perhaps others. However, only a limited number of 
OLIG2 interaction partners have been defined. In order to uncover new opportunities for indirect 
targeting of OLIG2,  we undertook a yeast two-hybrid screen using full-length OLIG2 and 
several truncated fragments as bait. A number of interesting candidates emerged from the 
human genome library, including a member of the Wnt pathway and a regulator of embryonic 
neurogenesis, both of which merit further study of their potential interplay with OLIG2 function 
and the capacity to target them for therapeutic benefit.   
 
Methods 
OLIG2 purification from human cells. OLIG2-V5-HIS cDNA was transiently transfected into 
COS-7 cells using the pcDNA3.1 vector. Following cellular lysis, the protein was purified by 
immunoprecipiation with V5 antibody (Sigma) and V5 peptide (Sigma) elution, followed by 
immunoprecipitation with Ni-NTA beads (Qiagen) and elution in 200 mM imidazole and Buffer A 
(50mM Tris, pH 7.5, 150mM KCl, 5mM MgCl2, 10% glycerol, 0.1% NP40, and protease 
inhibitors).  
 
Recombinant OLIG2 production.  GB1-OLIG2-His was expressed in Escherichia coli BL21 
(DE3) from the pGEV2 vector
32 and induced with 1 mM isopropylthio-β-galactoside for 4 hours 
at 30°C. Bacterial pellets were resuspended on ice in Buffer A (50 mM Tris, pH 7.5, 150 mM 
KCl, 5 mM MgCl2, 10% glycerol, 0.1% NP40, and protease inhibitors), lysed by microfluidization, 	 ﾠ 119	 ﾠ
and centrifuged at 45,000 rpm for 45 minutes at 4°C. Cleared lysate was purified by affinity 
chromatography using nickel-NTA agarose beads (Qiagen), followed by washes with Buffer A 
containing 5, 10, and 15 mM imidazole. GB1-OLIG2-His was eluted with Buffer B (50 mM Tris, 
pH 7.5, 150 mM KCl, 5 mM MgCl2, 250 mM imidazole), concentrated, and buffer exchanged to 
Buffer C (50 mM Tris, pH 7.5, 150 mM KCl, 5 mM MgCl2) to remove the imidazole. GB1-OLIG2-
His protein was further purified by gel filtration FPLC and ultimately stored in Buffer A.  Fractions 
were analyzed by gel electrophoresis, followed by Western blot analysis with and Olig2 antibody 
(gift from the Stiles lab, DFCI). 
 
Mass spectrometry identification of OLIG2.  Recombinant GB1-OLIG2 fractions purified by 
FPLC were electrophoresed using a 4%-12% gradient Bis-Tris gel (Invitrogen), and then stained 
for protein content by Coomassie Blue. The GB1-OLIG2 band at 45kD was excised and 
prepared for mass spectrometry analysis as previously described
40. Samples were subjected to 
LC-MS/MS in an LTQ Orbitrap XL hybrid mass spectrometer (ThermoFisher, San Jose, CA). 
MS/MS spectra were searched using the SEQUEST algorithm (Yates 1995) against a tryptic 
database of the human proteome.  
 
Stapled peptide synthesis and characterization. Stapled peptides were synthesized, 
derivatized, purified to >95% homogeneity by LC/MS, quantified by amino acid analysis, and 
subjected to circular dichroism (Aviv Biomedical spectrophotometer) in water as previously 
described
41,42. Singly stapled i,i+4 peptides employed (S)-N-Fmoc-2-(4ʼ-pentylenyl)alanine [S5] 
as both of the non-natural amino acids, whereas doubly-stapled i, i+7 peptides used (R)-N-
Fmoc-2-(7ʼ-octenyl)alanine [R8] for one of the non-natural amino acids of the staple pair and S5 
for the second. SAH-MYC2A: VVILXKATXYILS; SAH-MAX2A: RAQILXKATXYIQY 
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Electrophoretic mobility shift assays. OLIG2 protein (purified as described above) was 
quantified by silver stain against known concentrations of BSA protein. Oligonucleotides 
included the Hb9 and MycN E-box-containing promotors with the following DNA sequences: 
Hb9: 5ʼ AGCTAATTTCCCAGATGGGCCAA 3ʼ and 3ʼ AGCTTTGGCCCATCTGGGAAATT 5ʼ; 
MycN: 5ʼ AGCTAGAAGACAGCTGTTGGAAG 3ʼ and 3ʼ AGCTCTTCCAACAGCTGTCTTCT 5ʼ. 
In addition, negative control mutant sequences were also generated: Hb9 mutant : 5ʼ 
AGCTAATTTCCTAGACTGGCCAA 3ʼ and 3ʼ AGCTTTGGCCAGTCTAGGAAATT 5ʼ; MycN 
mutant: 5ʼ AGCTAGAAGATAGCCTTTGGAAG 3ʼ and 3ʼ AGCTCTTCCAAAGGCTATCTTCT 3ʼ. 
Oligonucleotides were annealed in annealing buffer (10 mM Tris [pH7.5], 50 mM NaCl, 1 mM 
EDTA) using a thermocycler for 5 min at 95°C, and allowed to cool down for approximately 1 
hour. The annealed probe was labeled with [α-
32P] 6000 Ci/mmol dCTP (PerkinElmer) using 
Klenow (New England Biolabs). The radioactive DNA probe was incubated with 2 ng of GB1-
OLIG2 protein in binding buffer (20 mM Tris [pH7.5], 5 mM MgCl2, 0.1% NP40, 0.5 mM DTT, 
10% glycerol) and increasing concentrations of SAH-OLIG2 peptides for 30 min at 4°C. 
Protein:DNA complex was analyzed using 4% non-denaturing poly-acrylamide gel 
electrophoresis (PAGE) for 30 min at 4°C. After drying the gel, radioactive signal was detected 
using a Typhoon 9400 (GE Healthcare Life Sciences). 	 ﾠ
 
Yeast two-hybrid screening.  Complete methods for the yeast two-hybrid screening have been 
described elsewhere
43. Olig2, Olig1, and Nkx2.2 constructs were amplified by PCR and cloned 
into pDONR entry vectors, followed by recombination into pDEST destination vectors containing 
an activating or DNA-binding domain, respectively (Gateway cloning system, Invitrogen). Olig2 
truncation fragments were as follows: FL Olig2 (1-972), Olig2ΔC (1-510), Olig2ΔN (277-972), 
Olig2 ext. bHLH (277-510), Olig2 bHLH (325-489), Olig2 HLH (361-489), Olig2 H1-Loop (361-	 ﾠ 121	 ﾠ
429), Olig2 Loop-H2 (406-489), Olig1 (1-816), Nkx2.2 (1-822). Completed plasmids were 
transformed into the yeast strains Y8800 MATa and Y8930 MATAα. For primary screening, a 
single bait was mixed in liquid yeast extract peptone dextrose (YEPD) with a single prey (for the 
10x10 screen) or with pools of approximately 200 preys, with the pools representing the entirety 
of the human genome
44. Diploids were then selected in liquid YEPD lacking leucine and 
tryptophan. Successful interaction of the bait and prey was identified by growth on YEPD plates 
containing 3-amino-1,2,4-triazole (3-AT). Auto-activators were discarded following growth on 
YEPD plates containing cyclohexamide. True hit colonies were lysed, PCRed, and submitted for 
Sanger sequencing to identify the relevant AD-X and DB-Y interacting constructs. To verify the 
interaction, individual hits were pulled from the database, and the screen repeated in a one-on-
one fashion. All stages of screening were completed using each construct fused to both AD and 
DB domains as bait. 
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Chapter 4 
 
Ongoing and Future Work 
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Work in Chapters 2 and 3 utilized stapled α-helical peptides to investigate and modulate 
known functions of the PUMA and OLIG2 proteins. However, much remains unknown about 
both proteins, including structural details of their protein interactions and alternative binding 
partners. Our ongoing work aims to use both full-length proteins and stapled peptides derived 
from them to explore these new frontiers in their biochemistry and cell biology. 
 
Identification of novel binding partners of PUMA 
The interplay among members of the BCL-2 family is well established as a mechanism 
of mitochondrial apoptosis regulation. However, additional “day jobs” and interaction partners 
have been identified for several BCL-2 proteins, including the regulation of calcium 
homeostasis
1, glucose metabolism
2,3, and mitochondrial fusion and morphogenesis
4. From a 
therapeutic perspective, knowledge of these additional roles is critical in order to anticipate and 
monitor potential side effects of therapies targeting BCL-2 proteins as well as leverage these 
roles for non-apoptotic therapies. However, the potential for noncanonical protein interactions 
remains an understudied area of BCL-2 biology, and we therefore have undertaken a 
proteomics study using both full-length proteins as well as our stapled peptides in order to 
investigate novel PUMA interacting proteins (Figure 4-1). 
 
Full-length PUMA protein pulldowns identify a variety of novel interaction partners 
  As a first step in elucidating new biological roles for PUMA, vectors containing Flag- or 
HA-tagged versions of PUMAα were generated and transiently transfected into human 
embryonic kidney (HEK) 293T cells. PUMA protein and associated proteins were 
immunoprecipitated using Flag or HA affinity beads and separated by gel electrophoresis. 
Sections of each gel lane were then excised and prepared for mass spectrometry analysis. 
From this analysis, a list of 650 proteins was identified, 365 of which were identified with both  	 ﾠ 128	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Figure 4-1 
 
Schematic of proteomics screen to identify novel PUMA interaction partners.  Our 
proteomics workflow began with identification of novel binding partners of the full-length PUMA 
protein. Hits were narrowed to those that directly bound to the PUMA BH3 domain using stapled 
peptides, first as affinity probes and then as covalent crosslinkers. All target identification was 
performed by LC/MS/MS analysis. 	 ﾠ 129	 ﾠ
Flag-PUMA and HA-PUMA pulldowns. Examination of those proteins using pathway enrichment 
software (Ingenuity Pathway Analysis) identified several protein pathways that were statistically 
upregulated in the immunoprecitations, including RNA post-transcriptional modification, 
molecular transport, RNA trafficking, and DNA replication, recombination, and repair (Table 4-
1). 
 
Stapled PUMA peptides identify direct PUMA BH3-binding proteins 
  While the pulldown of full-length PUMA protein provided a wealth of new information 
regarding putative PUMA interactions, we decided to restrict our focus to those proteins that 
interact directly with PUMA BH3, the only known functional domain of the protein. To do so, we 
made use of our previously generated PUMA stapled peptides, which we have shown 
recapitulate known PUMA binding interactions and function. Biotinylated PUMA SAHBA3 was 
incubated with U937 lymphoma cell lysates, and SAHB-protein complexes were captured with 
streptavidin agarose and analyzed by mass spectrometry, as above. A list of 840 proteins was 
identified, 235 of which were also identified in the protein pulldowns. These proteins represent 
those proteins that bind either directly to, or as part of a complex with, the BH3 domain of 
PUMA. 
In order to identify those proteins from the list that directly bind to PUMA BH3, we utilized 
photoreactive PUMA SAHB (PUMA pSAHB) peptides containing a benzophenone residue. 
Benzophenone moieties covalently bind to adjacent C-H bonds upon UV irradiation, allowing for 
stringent washes and identification of direct binders. U937 lymphoma cell lysates were 
incubated with biotinylated PUMA pSAHB-2, with or without UV irradiation, and complexes were 
captured by incubation with streptavidin agarose. Following a series of stringent washes, the 
proteins were separated by electrophoresis, and sections of each gel lane excised and analyzed 
by mass spectrometry, which identified 610 proteins. Of these proteins, 80 overlapped with both  	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Table 4-1 
 
Top four identified biological pathways of full-length PUMA interaction partners.  Analysis 
was performed using Ingenuity Pathway Analysis software 
 
 
 
Table 4-2 
 
Top four identified biological pathways of direct PUMA BH3 interaction partners.  
Analysis performed using Ingenuity Pathway Analysis software. 	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the full-length PUMA protein, PUMA SAHB, and PUMA pSAHB pulldowns. Pathway enrichment 
analysis of these 80 genes identified several pathways of potential interest with high statistical 
significance, including RAN signaling (nuclear import/export), tRNA charging, and DNA 
mismatch repair (Table 4-2). 
 
Initial validation of nuclear exportins as PUMA-interacting proteins 
One of the families identified as a direct binder of the PUMA BH3 domain was the 
exportin protein family, which regulates the process of nuclear export. Exportins circulate 
between the nucleus and cytoplasm carrying cargo through the nuclear pore, aided by Ran and 
the GTP-GDP gradient
5. There are a variety of exportin proteins, each having a specific subset 
of cargo. For instance, XPO-1 transports the majority of proteins that move out of the nucleus
6,7, 
while XPO-T moves tRNAs across the nuclear membrane
8,9.  
To confirm the interaction between PUMA and XPO, the Flag-PUMA and PUMA pSAHB-
2 pulldowns were repeated, and immunoprecipitated proteins were analyzed by Western blot. 
Both PUMA and PUMA pSAHB pulled down XPO5 (transports double-stranded RNA
10,11), which 
was one of the early top identified hits (Figure 4-2). Two potential functional roles for the 
interaction between PUMA and the exportins can be envisioned: 1) PUMA may be exported 
from the nucleus as exportin cargo or 2) PUMA may regulate the export process. To evaluate 
the possibility that PUMA might be cargo for an exportin protein, we blotted for and confirmed 
that PUMA protein can also bind to XPO1, the major exporter for proteins from the nucleus 
(Figure 4-3A). In contrast, expression and immunoprecipitation of Flag-BIM did not pull down 
XPO1 (Figure 4-3B), highlighting the specificity of the PUMA interaction. These preliminary 
data suggest that a previously undocumented functional interaction may exist between the 
PUMA BH3 domain and the exportin proteins, an interaction that may be specific to PUMA 
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Figure 4-2 
 
Full-length PUMA protein and biotinylated PUMA pSAHB both pull down native XPO5 
from mammalian cells.  (A) Human embryonic kidney (HEK) 293T cells were transiently 
transfected with vector or full-length Flag-PUMA protein. Complexes were captured with Flag 
affinity resin and analyzed by gel electrophoresis and Western blotting for XPO5. (B) Lysates 
from HEK 293T cells were incubated with biotinylated PUMA pSAHB-2 with and without 
ultraviolet light for benzophenone activation. Complexes were captured with streptavidin affinity 
resin and analyzed by gel electrophoresis and Western blotting for XPO5. In both cases, PUMA 
pulled down XPO5, confirming a PUMA-XPO5 interaction. 	 ﾠ 133	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Figure 4-3 
 
Full-length PUMA protein pulls down native XPO1, whereas BIM does not. 
Human embryonic kidney (HEK) 293T cells were transiently transfected with (A) vector or full-
length Flag-PUMA protein, or (B) vector or full-length Flag-BIML protein (with and without zVAD 
to prevent apoptosis). Complexes were captured with Flag affinity resin and analyzed by gel 
electrophoresis and Western blotting for XPO1. While PUMA successfully pulled down XPO1, 
BIM did not, highlighting the specificity of the PUMA-XPO1 interaction. 	 ﾠ 134	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Future directions 
In order to understand the interaction between PUMA and XPO, two areas of study will 
be pursued. First, structural analyses of PUMA-XPO binding using crosslinkable PUMA pSAHBs 
and recombinant XPO, as previously performed with PUMA pSAHBs and BCL-2 family proteins, 
will provide information regarding the binding interface. Such data could fuel hypotheses about 
the function of the interaction. Secondly, future biological studies will investigate the possibility 
that PUMA localization is regulated by XPO through the use of nuclear export inhibitors and 
subcellular fractionation or immunofluorescence imaging of PUMA. To investigate whether 
PUMA is regulating XPO function, changes in nuclear export will be evaluated in Puma
+/+ and 
Puma
-/- mouse embryonic fibroblasts. Taken together, these experiments will enable us to 
investigate how PUMA and XPO interact and what functional role a PUMA-XPO interaction 
might have in a cellular context.   
While we have piloted this proteomics platform with PUMA protein, SAHB, and pSAHB 
pulldowns, we are also interested in expanding this work to other BH3-only and BCL-2 family 
proteins. The BH3-only proteins BID and BIM, when coupled with PUMA, constitute the known 
direct activators of the multidomain pro-apoptotic proteins
12,13. While BID, BIM, and PUMA serve 
generally similar pro-apoptotic functions within the BCL-2 family, we hypothesize that, based on 
their differential expression patterns during development and homeostasis, distinguishing non-
traditional roles may exist.  A large scale proteomics effort will allow for the identification of novel 
interaction partners of BID, BIM, and PUMA, as well as enable a comparison between 
interactors of these three direct activator BH3-only proteins. Eventually, similar proteomic 
studies for all members of the BCL-2 family will expand our knowledge of how this diverse group 
of proteins work to regulate cellular processes, including apoptosis and beyond. 
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Structural and interaction analyses of OLIG2 
  Our attempts to modulate pathogenic OLIG2 activity using stapled peptides have thus far 
been unsuccessful, due to difficulties in obtaining specificity in targeting the bHLH dimerization 
domain of OLIG2. Looking ahead, we plan to investigate several approaches for targeting 
OLIG2, which will include structural, biochemical, and cellular studies of OLIG2 biology. 
 
Structural and biochemical studies using recombinant OLIG2 protein 
  Previous successes with stapled peptides have two things in common: a helix-in-groove 
binding interface, which increases the chance for specificity and potency of interaction
14-16; and 
detailed structural knowledge of the targeted interaction, either through mutagenesis, NMR, or 
crystallographic studies
13,17. At this stage, neither of these are the case for targeting the OLIG2 
dimerization domain. The interaction of the OLIG2 bHLH domain with its homodimeric partner is 
not a helix-in-groove interaction, but rather a helix-on-helix handshake, making this interface 
unique and perhaps more difficult to target by traditional and stapled peptide approaches. Since 
the inherent structural aspects of OLIG2 homodimerization cannot be altered, improvements in 
inhibitor (or stapled peptide inhibitor) design await high resolution structural determination of the 
homodimer. 
  Current structural information about OLIG2 can be derived from two sources. Secondary 
structure prediction programs suggest that OLIG2 has two α-helical domains separated by a 
short loop region, consistent with a bHLH domain (Figure 4-4). Additionally, high resolution 
structures have been obtained of the bHLH dimerization domains of homologous bHLH proteins, 
including the E47/NeuroD1
18 and cMYC/MAX heterodimers
19. While these data predict that the 
structure of an OLIG2 bHLH homo- or heterodimer is similar, confirmation of amino acid-level 
resolution can only be obtained by further structural studies of OLIG2 itself. 
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Figure 4-4 
 
Figure 4-4: OLIG2 has a predicted helix-loop-helix domain.  Secondary structure prediction 
program JPRED predicts two α-helices (green) in the OLIG2 structure, separated by a short 
loop region (red) and preceded by a string of basic residues (blue). 	 ﾠ 137	 ﾠ
Previously, structural determination has proven difficult due to the inability to generate 
recombinant OLIG2. However, as reported in Chapter 3, we are now able to generate milligram 
quantities of GB1-OLIG2 protein. This construct is functional in electrophoretic mobility shift 
assays (EMSAs), confirming that the generated protein can bind to DNA. We propose to use 
this recombinant protein in two ways to further our knowledge of OLIG2 structural biology. First, 
systematic mutagenesis of the bHLH domain, followed by screening for loss of function in 
EMSAs, will allow us to identify key residues critical for OLIG2 dimerization and/or DNA binding. 
While similar studies are possible using mutated Olig2 DNA constructs in a cellular environment, 
the use of recombinant protein and in vitro assays provides a more high-throughput system for 
evaluation. Secondly, generation of recombinant OLIG2 allows for the possibility of high-
resolution whole protein (or subdomain) structural analyses by NMR or X-ray crystallography. 
Future efforts will emphasize high purity isolation and optimization of conditions for such 
biochemical and structural experiments. Definitive structural information about the OLIG2 bHLH 
dimerization domain should allow for more sophisticated design of prototype therapeutics for 
OLIG2 targeting.  
 
Evaluation of putative interacting proteins of OLIG2 identified by yeast two-hybrid 
  bHLH proteins must homo- or heterodimerize with other bHLH proteins in order to carry 
out their transcriptional functions. Following DNA binding of promoter or enhancer elements, 
additional co-regulator proteins are recruited to the complex for the induction of transcriptional 
activation or repression
20,21. OLIG2 is known to both homodimerize and heterodimerize with 
OLIG1
22, and it associates with the co-regulator protein p300
23. However, the list of confirmed 
OLIG2 binding partners and co-regulator proteins remains quite short
22. In an effort to expand 
our knowledge of OLIG2 interaction partners, which may serve as useful indirect targets for 
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two-hybrid screen for direct OLIG2 binding partners (Chapter 3). From this screen, we identified 
a small number of high-confidence hits as candidate OLIG2 interaction partners (Figure 3-10, 
Chapter 3).  
By the nature of the yeast two-hybrid experimental system, the observed interactions 
were identified in a yeast cell environment and may not be representative of endogenous human 
protein interactions. Initial efforts have been made to validate these putative interactions in 
mammalian cells. Indeed, pulldown of OLIG2 from cultured mouse neurospheres successfully 
immunoprecipitated DVL3, a component of the Wnt signaling pathway and one of the hits from 
the yeast two-hybrid screen (Figure 4-5). Ongoing studies will continue these validation efforts 
using endogenous protein in order to confirm the biological relevance of the observed 
interactions. 
Preliminary examination of the identified interaction candidates revealed that two of the 
proteins, DVL3 and LNX2, contain a PDZ protein interaction domain 
24,25. This similarity 
suggests that the PDZ domain could be important for the interaction between OLIG2 and 
DVL3/LNX2, as well as other unknown binding partners. This hypothesis will be tested using 
mutations or deletions in the PDZ domain of DVL3 and LNX2, followed by immunoprecitation 
with OLIG2. Further cellular and biochemical studies will be performed using such constructs, as 
well as strategically mutated constructs of OLIG2, to dissect the structural and biochemical 
nature of these interactions. Ultimately, cellular experiments will be designed to explore 
biological relevance, which could provide an opportunity to modulate OLIG2 indirectly by 
targeted disruption of these novel protein-protein interactions.  
 
Summary 
  This thesis research has focused on the mechanistic dissection and therapeutic 
targeting of two proteins implicated in neuroectodermal pathology, PUMA and OLIG2. While the  	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Figure 4-5 
 
OLIG2 binds to DVL3 in mouse neurospheres. Subcellular fractionation of mouse 
neurospheres in culture, followed by immunoprecipitation of OLIG2, identified DVL3 as an 
OLIG2 interaction partner in the nuclear fraction. 
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primary biological interactions of both proteins are well-documented, additional interaction 
partners may play an important role in their biology and open new doors for therapeutic 
intervention. Initial work has been carried out to identify and characterize novel interaction 
partners for both PUMA and OLIG2 using a diverse set of experimental techniques, include 
mass spectrometry-based proteomics, stapled peptide-based protein capture and targeting, and 
yeast two-hybrid screening. Future interrogation of these interactions will include structural 
analyses, studies that will be aided by our successful production of recombinant OLIG2 protein. 
 
Methods 
Stapled peptide synthesis and characterization. SAHBs were synthesized, derivatized, 
purified to >95% homogeneity by LC/MS, quantified by amino acid analysis, and subjected to 
circular dichroism (Aviv Biomedical spectrophotometer) in 5 mM potassium phosphate buffer, 
pH 7.4, as previously described
26,27. Biontinylated PUMA SAHBA3: Btn-βAla-
QWAREIGAQLRXBADXLNAQY; biotinylated PUMA pSAHB-1: Btn-βAla- 
QWARXIGAXLRRBADDUNRQYE; biotinylated PUMA pSAHB-2: Btn-βAla- 
QUAREIGAQLRXBADXLNAQYE. X = (S)-N-Fmoc-2-(4ʼ-pentylenyl)alanine [S5]; U = 4-
benzoylphenylalanine, B = norleucine.  
 
Puma/Bim DNA constructs, cell transfection, and Flag co-immunoprecipitation.  HEK 
293T cells were transiently transfected with pcDNA3 plasmid containing Flag-PUMAα or Flag-
BIML using polyethylenimine
28 (PEI) at a 4:1 PEI:DNA ratio. Two days following transfection, 
cells were lysed in 1% CHAPS buffer (50 mM Tris [pH 7.5], 200 mM NaCl, 1% [w/v] CHAPS, 1 
mM EDTA, 1.5 mM MgCl2, complete protease inhibitor tablet [Roche]) on ice for 20 minutes. 
Lysates were isolated after table top centrifugation and then incubated with 30 mL of anti-Flag 
magnetic affinity beads (Sigma) in lysis buffer for 2 hours at room temperature. The beads were 	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washed with 3 x 500 mL lysis buffer, and immunoprecipitated proteins eluted by incubation with 
4x FLAG peptide for 1 hour at 4°C. The immunoprecipitates were subjected to electrophoresis 
and analyzed by western blot or by LC/MS/MS (see below for complete methods). Antibodies: 
PUMA H-136 (sc-28226, Santa Cruz Biotechnology), BIM 22-40 (202000, EMD Biosciences), 
XPO1 H-300 (sc-5595), XPO5 H-300 (66885). 
 
PUMA SAHB co-precipitation from cellular lysates.  U937 cells were collected by 
centrifugation, washed twice in cold PBS, and lysed in a 1% CHAPS buffer (50 mM Tris [pH 
7.5], 200 mM NaCl, 1% [w/v] CHAPS, 1 mM EDTA, 1.5 mM MgCl2, complete protease inhibitor 
tablet [Roche]), on ice for 20 minutes. Lysates were isolated after table top centrifugation and 
then incubated (1.25 mg) with 50 nmol biotinylated-PUMA SAHBA3 in lysis buffer overnight at 
4°C. Biotin pull down was accomplished by incubation with high-capacity streptavidin agarose 
(Thermo) for 2 hours at 4°C, followed by washing the beads with 3 x 500 mL lysis buffer. 
Proteins were eluted with 1x LDS and precipitated using trichloroacetic acid. Pellets were 
washed with cold acetone, followed by trypsinization and sample clean-up as previously 
described
29 Samples were analyzed by LC/MS/MS (see below for complete methods).  
 
PUMA pSAHB co-precipitation from cellular lysates.  HEK 293T cells were trypsinized, 
collected by centrifugation, washed twice in cold PBS, and lysed in a 1% CHAPS buffer (50 mM 
Tris [pH 7.5], 200 mM NaCl, 1% [w/v] CHAPS, 1 mM EDTA, 1.5 mM MgCl2, complete protease 
inhibitor tablet [Roche]), on ice for 20 minutes. Lysates were isolated after table top 
centrifugation, mixed with 40 nmol of biotinylated PUMA pSAHB-1 or -2, and irradiated (365 nm, 
Spectroline Handheld UV Lamp Model En280L, Spectronics Corp.) for 1.5 hours on ice. 
Biotinylated species were captured by incubation with high-capacity streptavidin agarose 
(Thermo) for 2 hours at 4°C. Streptavidin beads were sequentially washed at room temperature 	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three times each in 1% SDS in PBS, 1 M NaCl in PBS, and 10% ethanol in PBS, boiled 2 x 10 
minutes in a 10% SDS solution (Promega) containing D-biotin (10 mg/ml), and the eluates 
electrophoresed. Samples were analyzed by Western blot or by LC/MS/MS (see below for 
complete methods). Antibodies: XPO5 H-300 (66885). 
 
Protein identification by chromatography and spectrometry.  Electrophoresed samples 
were excised and prepared for mass spectrometry analysis as previously described
29. Samples 
were subjected to LC/MS/MS using an LTQ Orbitrap Discovery hybrid mass spectrometer 
(ThermoFisher, San Jose, CA). MS/MS spectra were searched using the SEQUEST algorithm
30 
against a partially tryptic human protein database for protein identification. Reversed protein 
sequences were used to generate an estimate of the false discovery rate.  
 
Subcellular fractionation.  Cultured primary mouse neural progenitor cells were collected and 
treated with 5x packed cell volume (pcv) hypotonic buffer (10 mM HEPES [pH 7.9], 1.5 mM 
MgCl2, 10 mM KCl), and centrifuged at 6000 rpm to collect nuclei. The supernatant was treated 
with 0.11x pcv 10x cytoplasmic extract buffer (0.3 M HEPES [pH 7.9], 1.4 M KCl, 0.03 M MgCl2). 
Cell nuclei were incubated in a mild salt buffer (20 mM HEPES [pH7.9], 10% glycerol, 1.5 mM 
MgCl2, 0.2 mM EDTA, 150 mM KCl) for 10 minutes on ice and rotated for 10 minutes at 4°C. 
The soluble nuclear protein fraction was collected by centrifugation at 10,000xg. All buffers were 
supplemented with protease inhibitors (Roche), 1mM NaVO4, 5 mM NaF, 1 mM Na4P2O7, 25 
mM beta-glycerophosphate and 0.5 mM PMSF.  
 
OLIG2 immunoprecipitation and immunoblotting.  Olig2
-/- null mouse neural progenitor cells 
were transduced with retrovirus encoding V5-tagged OLIG2 constructs. Subcellular fractions 
were generated as described above, and each fraction was incubated with V5 (Sigma) or Myc 	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(Sigma) antibodies overnight, rotating at 4°C. Antibody-bound fractions were washed four times 
in buffer B (50 mM Tris [pH 7.5], 100 mM KCl, 5mM MgCl2, 10% glycerol, 0.1% NP40) over bio-
spin columns (Biorad) and incubated with 0.5 mg/mL V5 peptide for 30 minutes at 4°C. 
Immunopurified fractions were collected by centrifugation at 8,000 rpm for 1 minute at 4°C and 
analyzed by standard SDS-PAGE followed by Western analysis. Antibodies: rabbit polyclonal 
OLIG2 (Stiles lab, DFCI), DVL3 (Cell Signaling Technology #3218).  
 
Attributions 
Contributions to this part of the thesis were made by Amanda L. Edwards, Dimphna H. Meijer, 
and Loren D. Walensky. 
 
A.L.E. and L.D.W. designed all PUMA SAHB constructs and experiments. A.L.E. performed all 
PUMA experiments and mass spectrometry analysis. D.H.M. performed the OLIG2-DVL3 
validation pulldowns. 
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Chapter 5 
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Discussion of results 
Mechanistic dissection of PUMA BH3 domainʼs role in promoting apoptosis 
The BCL-2 family of proteins regulates the ultimate decision of a cell to live or die 
through the intrinsic pathway of apoptosis. Interplay among these family members is a complex 
network of signal propagation, ligand-induced activation, inhibitory binding, and homo-
oligomerization. Knowledge of these interactions has led to therapeutic modulation of apoptosis, 
activating neutralized pro-apoptotic proteins and inhibiting overexpressed anti-apoptotic 
proteins. While this may suggest that the series of biochemical steps that leads to activation (or 
avoidance) of mitochondrial apoptosis is fully understood, the reality is that there is still much to 
be learned about how these proteins operate within the family, and with other proteins, to 
govern cellular viability. 
PUMA (p53-upregulated modulator of apoptosis) is a BH3-only pro-apoptotic protein that 
functions as a downstream effector of p53-driven death, following such stressors as DNA 
damage, irradiation, and hypoxia. In order to gain a better understanding of the mechanisms by 
which PUMA drives apoptosis forward, we made use of hydrocarbon-stabilized PUMA BH3 
domain peptides to study PUMA-BCL-2 family interactions. PUMA SAHB directly bound to both 
anti- and pro-apoptotic members. While contact with the anti-apoptotic proteins was found 
exclusively in the canonical BH3 binding grove, PUMA SAHB engaged the pro-apoptotic protein 
BAX at both the α1/α6 trigger site and at the canonical BH3 pocket. Additional NMR and 
photocrosslinking studies suggested two sequential binding events: primary binding at the α1/α6 
trigger site to allosterically release the α1/α2 loop and α9 C-terminal helix, and secondary 
binding in the vacated canonical binding pocket for further downstream activation. These 
sequential steps of activation lead to interesting questions about the potential role of a 
secondary binding event and the spectrum of BH3-only proteins that could execute such a step. 	 ﾠ 148	 ﾠ
Notably, PUMA SAHB was found to directly activate BAX in a membrane system, suggesting a 
functional consequence for its direct binding interaction. 
Among the BH3-only proteins, PUMA has been shown to be of particular importance in 
the induction of apoptosis of neural precursor cells. To evaluate the ability of PUMA SAHB to 
stimulate apoptosis in these cells, a cell-permeable version of PUMA SAHB was generated. 
Incubation of a variety of neuroblastoma cell lines with this peptide induced caspase 3/7-
dependent apoptosis. Cellular targets of PUMA SAHB and full-length PUMA protein were 
determined to include both anti- and pro-apoptotic BCL-2 family members, implying a 
multimodal mechanism of apoptotic targeting by this BH3-only protein. 
To date, the mechanisms by which PUMA induces apoptosis have remained 
controversial, with substantial experimental effort put towards a more complete understanding of 
PUMAʼs function. This work has utilized biochemical and structural approaches with stapled 
peptides, coupled with cellular work using full-length protein, to definitively answer this question. 
Like the BH3-only proteins BIM and BID, PUMA is able to directly bind and activate the 
proapoptotic executioner protein BAX. In addition to addressing an ongoing scientific debate, 
the binding determinants for BID, BIM, and PUMA at the trigger site of BAX will also facilitate 
ongoing projects to target proapoptotic molecules for direct activation of apoptosis.  
 
Targeting pathogenic OLIG2 transcription using stabilized α-helical peptides 
  Induction of cell death in neuroblastomas with stabilized PUMA peptides is one 
mechanism for therapeutic intervention in diseases of neural precursor cell origin. While PUMA 
activity is not specific to neuronal cells, aberrant expression of the protein OLIG2 is exclusively 
found in gliomas and is thus a potentially ideal therapeutic target. 
A member of the bHLH transcription factor family, OLIG2 is an early regulator of central 
nervous system development, maintaining neural precursor cells in a replication-competent 	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state until ultimately driving them toward differentiation. Beyond its developmental role, OLIG2 is 
expressed in all diffuse human gliomas and is required for glioma formation. Both of these roles 
stem from OLIG2ʼs function as a transcription factor. bHLH transcription factors, including 
OLIG2, must dimerize through their bHLH domains to stably engage regulatory DNA sequences 
and recruit additional co-regulator proteins. Disruption of this dimerization could thus ablate 
pathogenic OLIG2-mediated transcription. 
A synthesized panel of stabilized OLIG2 and E12 Helix 1, Helix 2, and bHLH peptides 
exhibited a spectrum of α-helical stabilization, ranging from 23-100% α-helicity in solution. 
Unfortunately, analysis of all SAH-OLIG2 and -E12 peptides by electrophoretic mobility shift 
assay did not identify a construct capable of  specifically disrupting an OLIG2 homodimer/DNA 
complex. Several of the peptides exhibited nonspecific binding to the DNA, in large part due to 
the high positive charge of many of the sequences. However, this effect was partially abrogated 
by the addition of excess nonspecific DNA to the EMSA system. Taken together, these data 
suggest that our current library of stapled peptides corresponding to the dimerization domain of 
bHLH proteins is unable to specifically and potently disrupt the obligate dimerization for OLIG2 
transcriptional activity. 
Since, thus far, we have been unable to target OLIG2 directly, we decided to search for 
OLIG2 interaction proteins that might serve as indirect targets using a yeast two-hybrid 
approach. Whole genome screening with full-length and truncated OLIG2 constructs resulted in 
a limited list of high-confidence candidate OLIG2 interaction partners, including DVL3 and 
LNX2. Future work will investigate the roles of such interactions in OLIG2 biology and whether 
they are amenable to therapeutic targeting. 
  In the course of these studies, it became apparent that the generation of a recombinant 
form of OLIG2 would greatly facilitate biochemical and structural studies of this key pathogenic 
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challenges. As an extension of this thesis research, we have now successfully generated and 
purified milligram quantities of GB1-tagged OLIG2 in E.coli. This protein product was functional 
in an EMSA assay using a verified OLIG2 target DNA sequence. We anticipate that this 
recombinant protein will prove valuable for OLIG2 structural determination and small molecule 
screens.  
  While our efforts to therapeutically target OLIG2 using stapled peptides have yet to yield 
a prototype tool reagent, our ongoing work to further elucidate OLIG2 structural biology and 
binding partners will hopefully produce new leads for future targeting. If we are able to learn how 
to target the bHLH dimerization domain of OLIG2, using stapled peptides or derivatives of such 
peptides,  this will potentially provide new opportunities to target the range of high-profile bHLH 
transcription factor targets, including proteins such as MYC and MAX. 
   
Considerations 
Structured peptide versus whole protein biology 
  In both major projects that comprise this thesis, chemically-stabilized peptides were 
generated to mimic an essential structured domain of the target protein. A primary consideration 
in executing such studies is whether or not the peptide mimetic will accurately represent the 
binding specificity and function of the full-length protein. PUMA SAHB was determined to bind to 
the full array of recombinant anti-apoptotic proteins, in accordance with published data for 
PUMA protein. In addition, when immunoprecipitated from cellular lysates, both PUMA SAHB 
and PUMA protein bound to the native anti-apoptotic proteins MCL-1 and BCL-2 as well as the 
pro-apoptotic protein BAX. These experiments indicate that PUMA SAHB, a structurally 
accurate version of the bioactive domain of the PUMA protein, is capable of correctly targeting 
native PUMA interactors for functional analyses. In contrast, SAH-OLIG2 peptides were unable 
to bind and disrupt OLIG2 homodimers in vitro, suggesting that such peptides are either 	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incapable of simulating bHLH function or that the “hot spots” for dimer disruption, and the 
peptidic means for targeting them, have not been adequately determined.   
  The structural distinctions between these two classes of protein-protein interactions  - 
helix-in-groove vs. intertwined helices - are critical when considering how to best design and 
apply structured peptides for biological studies and therapeutic targeting. In the case of PUMA 
interactions, PUMA SAHBS were effective surrogates for the native full-length protein, 
recapitulating its pro-apoptotic functions and simulating its key interaction domain for trapping 
known binding partners and identifying candidate novel interactors (as suggested in Chapter 4). 
However, the current iteration of SAH-OLIG2 peptides failed to substitute for the OLIG2 bHLH 
domain or full-length OLIG2. In both cases, careful consideration must be given to potential 
drawbacks of using a short peptide to represent the protein as a whole, including loss of 
regulatory post-translational modifications, localization sequences, and differential splice 
variants. Nevertheless, stapled α-helical peptides have proven to be powerful mechanistic tools 
and prototype therapeutics in dissecting a variety of therapeutically relevant helix-in-groove 
protein interactions. 
 
Future generations of stapled peptides 
  Peptides designed to mimic native α-helices have been a work-in-progress for decades, 
with hydrocarbon stapling successfully transforming unfolded peptides into proteolytically stable, 
α-helical peptides. However, much remains to be learned and accomplished. As detailed above, 
PUMA SAHB was able to potently bind to BCL-2 family member targets, while α-helical SAH-
OLIG2 peptides failed to bind and disrupt full-length OLIG2 dimers, despite significant excess of 
the SAH-OLIG2 peptides and the ability of truncated protein fragments of the bHLH domain of 
other bHLH transcription factors to dimerize with one another. This dichotomy is consistent with 
known differences in the binding interfaces of these two interactions. BH3 α-helices bind into 	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hydrophobic binding grooves, which may themselves provide favorable energetics for high 
affinity ligand engagement. However, the α-helices of the bHLH domain of OLIG2 crisscross 
upon one another, limiting the number of potential high affinity contacts. It is therefore likely that 
additional constraints and contact points from the rest of the protein are necessary to support 
the dimerization interaction, providing the optimal context for bHLH domain dimerization. 
Although stapled peptides have yet to simulate this interaction, new opportunities for OLIG2 
structural determination may provide the blueprint for optimizing the stapled peptide designs.  
To potentially broaden the utility of stapled peptides for engaging diverse protein 
surfaces, new design considerations are envisioned. For example, to increase the affinity for 
interaction surfaces adjacent to DNA, such as in targeting bHLH domains, joining two targeting 
molecules, a stapled peptide to engage the α-helical interaction surface and a polyamide group 
to specifically target the adjacent DNA sequence, may represent an optimal design. 
Alternatively, a peptide-nucleic acid hybrid may achieve the desired targeting properties.  To 
match the diverse topographic landscape of protein-protein interactions, new generations of 
stapled peptides with discrete chemical and structural enhancements may serve to expand this 
promising new chemical toolbox for protein interaction discovery and therapeutic targeting.   
 
 